Document:

Exhibit 10.18

 

Dated [•] June 2015

 

 

 

JEFFERIES LOANCORE (EUROPE) LIMITED

as Seller

 

 

and

 

 

LCRT HOLDINGS LLC

as Purchaser

 

 

_____________________________________________

 

JEFFERIES LOANCORE (EUROPE) LIMITED 

 

UK LOAN SALE AGREEMENT

_____________________________________________

 

 

Paul Hastings (Europe) LLP

Ten Bishops Square, Eighth Floor

London E1 6EG

Tel: +44 (0) 20 3023 5100

Fax: +44 (0) 20 3023 5109

 

    	 

    	 

    

Table
of Contents

 

Page

 

	1.   	DEFINITIONS AND INTERPRETATION	1
	2.   	SALE AND PURCHASE	4
	3.   	ASSURANCE	6
	4.   	CONSIDERATION	6
	5.   	CO-OPERATION	6
	6.   	COMPLETION	7
	7.   	WARRANTIES AND REPRESENTATIONS	8
	8.   	NO AGENCY OR PARTNERSHIP	10
	9.   	PAYMENTS	10
	10.   	LIABILITY	10
	11.   	NON PETITION	10
	12.   	WAIVER	11
	13.   	NOTICES	11
	14.   	VARIATIONS	11
	15.   	COUNTERPARTS	12
	16.   	GOVERNING LAW AND JURISDICTION	12
	SCHEDULE 1  REPRESENTATIONS AND WARRANTIES	13
	SCHEDULE 2  COMPLETION DELIVERABLES	16

 

    	- i -

    	 

    

THIS AGREEMENT is made on [•]
June 2015

 

BETWEEN:

 

		(1)	JEFFERIES LOANCORE (EUROPE) LIMITED, a company registered in Ireland with company number 542933 whose registered address
is at Pinnacle 2, EastPoint Business Park, Dublin 3, Ireland as lender (the “Seller”); and

 

		(2)	LCRT HOLDINGS LLC, a Delaware limited liability company, whose registered office is at 55
Railroad Ave. #100 Greenwich, CT 06830 USA (the “Purchaser”).

 

WHEREAS:

 

		(A)	The Seller owns the Neptune Loan and the PBN B2 Note Loan.

 

		(B)	On the terms and subject to the conditions of this Agreement, the Seller has agreed to sell and
the Purchaser has agreed to purchase the Loans.

 

IT IS HEREBY AGREED AS FOLLOWS:

 

		1.	DEFINITIONS AND INTERPRETATION

 

		1.1	Definitions

 

“Borrower” means,
with respect to each Loan, each “Borrower” with respect to that Loan;

 

“Borrower Facility Agent”
means Situs Asset Management Limited in its capacity as facility agent and any successor or assignee thereof under the Loan Agreements;

 

“Borrower Security Trustee”
means Situs Asset Management Limited in its capacity as borrower security trustee and its successors and assigns pursuant to the
Loan Security Agreements;

 

“Closing Date”
means the date on which the transfer of the Mortgage Loans shall be made being on or about 7 July 2015 at the time agreed upon
by the parties;

 

“Custodian”
means any custodian appointed by Purchaser to accept custody of the Mortgage File.

 

“Duty of Care Agreement”
means the duty of care agreement pursuant to which the Property Manager has undertaken to exercise reasonable skill, care and diligence
in performing its obligations under the Property Management Agreement and to comply in full with the terms of and fulfil its obligations
set out in the Property Management Agreement;

 

“Fee Letter”
means any letter between, amongst others, the Borrower Facility Agent, the Borrower Security Trustee and the Borrowers setting
out certain fees payable in relation to the Loan Agreements;

 

“Guarantor”
means each guarantor under the Loan Agreements;

 

    	1

    	 

    

“Intercreditor Deed”
means the intercreditor deed dated 21 January 2015 between, amongst others, the Seller, the Borrower Security Trustee and the Borrower
Facility Agent relating to the PBN Whole Loan;

 

“Loan” means
each of the PBN B2 Note Loan and the Neptune Loan;

 

“Loan Agreements”
means the Neptune Facility Agreement and the PBN Facility Agreement;

 

“Loan Documents”
means, each Loan Agreement, each Fee Letter, each Duty of Care Agreement, each transfer certificate, each utilisation request,
each accession letter, the Intercreditor Deed, the PBN B Note Intercreditor Deed, each Loan Security Agreement, and any other document
designated as such by the Borrower Facility Agent;

 

“Loan Security Agreement”
means any security agreement (howsoever described) pursuant to which the Obligors have created, inter alia, mortgages over
the Properties, and/or mortgages or security interests over any shares or units in the Property Owners, assignments of rents, account
pledges and floating charges or any other security, guarantee, indemnity or other assurance to secure their respective obligations
under the Loan Documents;

 

“Mortgage” means
a security interest in land created by a written instrument securing the payment of a debt owed by the Borrower to the Borrower
Security Trustee, granting the Borrower Security Trustee a first ranking legal mortgage over the relevant Property and the related
liquidation proceeds upon enforcement;

 

“Mortgage File”
means copies of the documents listed below pertaining to the Loans:

 

		(a)	the Loan Agreements and all amendments and supplements thereto;

 

		(b)	the Mortgages and/or other Loan Security Agreements for each Property;

 

		(c)	environmental reports of the Properties in connection with the origination of the Loan;

 

		(d)	property management agreement and property adviser agreement or similar agreements for each Property;

 

		(e)	the Intercreditor Deed;

 

		(f)	the PBN B Note Intercreditor Deed;

 

		(g)	all amendment, assumption, modification, written assurance and substitution agreements, in those
instances where the terms or provisions of the Loan Agreement, any mortgage or any related security document or other document
listed herein have been modified; and

 

		(h)	any guarantee of the obligations of the Borrowers under the Loans.

 

    	2

    	 

    

“Mortgagor”
means the grantor of a Mortgage;

 

“Neptune Facility Agreement”
means the £13,157,500 facility agreement dated 11 September 2014 between Aube Property Holdings Limited as borrower, Jefferies
LoanCore (Europe) Limited as original lender and Situs Asset Management Limited as Facility Agent and Security Trustee;

 

“Neptune Loan”
means the loan made pursuant to the terms of the Neptune Facility Agreement which, as of the date of this Agreement, has an outstanding
principal balance of £11,169,997.01;

 

“Obligor” means
each Borrower and each Guarantor;

 

“Original Valuation”
means the independent valuation of the related Property or Properties provided to the Seller on or around the date of each Loan;

 

“PBN A Note”
means the senior tranche of the PBN Whole Loan which as of the date of this Agreement has an outstanding principal balance of £69,682,998;

 

“PBN B Note Intercreditor
Deed” means the intercreditor deed to be entered into on or about the Closing Date between lenders of the PBN B1 Note
Loan, the PBN B2 Note Loan and the PBN B3 Note Loan, the Borrower Security Trustee and the Borrower Facility Agent relating to
the PBN B1 Note Loan, the PBN B2 Note Loan and the PBN B3 Note Loan;

 

“PBN B1 Note Loan” means a subordinate tranche of the PBN Whole Loan which as of the date of this Agreement has
an outstanding principal balance of £5,807,410 and pursuant to the Intercreditor Deed and the PBN B Note Intercreditor Deed
ranks junior to the PBN A Note but senior to the PBN B2 Note Loan and the PBN B3 Note Loan;

 

“PBN B2 Note Loan”
means a subordinate tranche of the PBN Whole Loan which as of the date of this Agreement has an outstanding principal balance of
£19,983,501 and pursuant to the Intercreditor Deed and the PBN B Note Intercreditor Deed ranks junior to the PBN A Note and
PBN B2 Note Loan but senior to the PBN B3 Note Loan;

 

“PBN B3 Note Loan”
means a subordinate tranche of the PBN Whole Loan which as of the date of this Agreement has an outstanding principal balance of
£14,176,091 and pursuant to the Intercreditor Deed and the PBN B Note Intercreditor Deed ranks junior to the PBN A Note,
the PBN B1 Note Loan and the PBN B2 Note Loan;

 

“PBN Facility Agreement”
means the £109,650,000 facility agreement dated 21 January 2015 between, inter alios, the Kilmona Investments Limited
as borrower, Jefferies LoanCore (Europe) Limited as the original lender and Situs Asset Management Limited as security trustee
and facility agent;

 

“PBN Whole Loan”
means the loan made pursuant to the terms of the PBN Facility Agreement which, as of the date of this Agreement, has an outstanding
principal balance of £109,650,000;

 

    	3

    	 

    

“Property” means
each property securing the obligations of the Obligors under the Loans, and “Properties” means any or all of them,
as the context requires;

 

“Property Owners”
means the owner of a Property;

 

“Property Manager”
means a property manager appointed pursuant to a Property Management Agreement in relation to a Property as permitted under the
terms of a Loan Agreement;

 

“Property Management
Agreement” means a property management agreement with respect to a Property entered into in relation to the Loan Agreement;

 

“Purchaser Assets”
means the Loans and the Purchaser’s interest in the Related Security and all monies derived therefrom from time to time,
which will be sold to the Purchaser on the Closing Date;

 

“Related Security”
means, collectively, the Loan Security Agreements, the Duty of Care Agreement and any other security agreements securing the Loans;

 

“Repurchase Price”
means a price equal to the sum of the following (in each case, without duplication) as of the date of such repurchase: (i) the
then outstanding principal balance of the relevant Loan, discounted based on the percentage amount of any discount that was applied
when such Loan was purchased by the Purchaser, plus (ii) accrued and unpaid interest on such Loan, plus (iii) any unreimbursed
advances, plus (iv) accrued and unpaid interest on advances on the Loan, plus (v) any reasonable costs and expenses (including,
but not limited to, the cost of any enforcement action, incurred by the Purchaser in connection with any such repurchase by the
Seller); and

 

“Transfer Certificate”
means, as the context requires, a transfer certificate substantially in the form of transfer certificate scheduled to the Loan
Agreements.

 

		1.2	For the purposes of this Agreement, save where the context otherwise requires any references to
“Related Security” means the Seller’s interest (in its capacity as lender in respect of the Neptune Loan
and the PBN B2 Note Loan only) immediately prior to the Closing Date in the Loan Security Agreements, the Duty of Care Agreement
and any other security agreements securing the Loans that are transferred hereunder.

 

		2.	SALE AND PURCHASE

 

		2.1	Sale and Purchase

 

Subject to
the terms and conditions of this Agreement, the Seller agrees to transfer to the Purchaser all of its rights and obligations, title,
interests and benefits (present and future), in each case, in its capacity as lender, in, to, under and/or connected with the Loans
and its interest in the Related Security with respect to the Loans.

 

    	4

    	 

    

		2.2	Terms of Sale

 

It shall be a term of the transfer
referred to in Clause 2.1 (Sale and Purchase) above that the Seller, with full title guarantee as lender in relation to
the Loans shall transfer on the Closing Date:

 

		(a)	subject to the subsisting rights of redemption of the Borrowers, all rights, title interests and
benefits of the Seller (both present and future) in its capacity as lender in, to, under and/or connected with the Loans, and its
interest in the Related Security with respect to the Loans including, for the avoidance of doubt and without limitation:

 

		(i)	its right as lender to demand, sue for, recover, receive and give receipts for all moneys payable
or to become payable in respect of the Loans; and

 

		(ii)	its benefit of and its right to sue on all covenants with and undertakings to or for its benefit
in respect of the Loans, as applicable, and its interest in the Related Security with respect to the Loans and its right to exercise
all rights and powers of the Seller in relation to the Loans, as applicable; and

 

		(iii)	all estate, title and interest in the Properties vested in the Seller as security for the Loans,
subject to redemption or cesser; and

 

		(iv)	all reports, valuations, opinions, certificates and consents given in connection with the Loans,
which are assignable or transferable to the Purchaser and all of its causes and rights of action against any person in connection
with any report, valuation, opinion, certificate, consent or other statement of fact or opinion given in connection with the Loans,
as applicable;

 

		(v)	(subject to the subsisting rights (if any) of a Mortgagor) all the estate, rights, title, interests
and benefits of the Seller in each insurance policy taken out in respect of the Properties including, without limitation, the right
(if any) to receive the proceeds of any claim;

 

		(vi)	all scheduled payments of interest and principal due on or with respect to the Loans after the
Closing Date; and

 

		(vii)	all other payments of interest, principal, indemnities for costs and expenses or any other amounts
received on or with respect to the Loans after the Closing Date.

 

		(b)	all rights under all subordination or intercreditor agreements relating to the Loans, (including,
without limitation, with respect to the PBN B2 Note Loan, the Intercreditor Deed and the PBN B2 Note Loan).

 

		2.3	Transfers and Assignments

 

		(a)	The transfer of the Loans and the Seller’s interest in the Related Security with respect
to the Loans will be effected by execution by the Seller, the Purchaser and the Borrower Facility Agent of a Transfer Certificate
with respect to each Loan in the form required pursuant to the respective Loan Agreement.

 

		(b)	In addition to the Transfer Certificates, with respect to the sale of the PBN B2 Note Loan, the
Purchaser shall also execute a deed of accession to the Intercreditor Deed and the PBN B Note Intercreditor Deed in the form required
pursuant to thereto and deliver the same to the Borrower Facility Agent.

 

    	5

    	 

    

		2.4	Transfer of Related Security

 

The Seller, in consideration
of the amounts payable in terms of Clause 4 (Consideration) and subject only to satisfaction of the conditions referred
to in Clause 6.1 (Conditions Precedent), hereby assigns (to the extent if any not otherwise assigned pursuant to Clause
2.3 (Transfers and Assignments)) to and in favour of the Purchaser with effect from the Closing Date all of the rights,
title, interests and benefits of the Seller, present and future, in and to its interest in the Related Security with respect to
the Loans and the security trusts insofar as they relate to the Loans in terms of which such interests in the Related Security
is held by the Borrower Security Trustee.

 

		2.5	Trust

 

If, on (or at any time after)
the Closing Date, the Seller holds, or there is held to its order, or the Seller receives, or there is received to its order, (otherwise
than following a repurchase under Clause 7.4 (Remedy for Material Breach) any property, interest, right or benefit hereby
agreed to be sold or transferred and/or the proceeds thereof, the Seller undertakes with the Purchaser that it will hold such property,
interest, right or benefit and/or the proceeds thereof upon trust for the Purchaser as the beneficial owner thereof or as the Purchaser
may direct and in the case of proceeds shall forthwith pay such proceeds to such account as the Purchaser may specify. Similarly,
if at any time after the Closing Date the Purchaser holds, or there is held to its order, or it receives, or there is received
to its order, any property, interest, right or benefit which is repurchased by the Seller under Clause 7.4 (Remedy for Material
Breach) and/or the proceeds of any thereof, the Purchaser undertakes with the Seller that it will hold such property, interest,
right or benefit and/or the proceeds thereof upon trust for the Seller as beneficial owner thereof or as the Seller may direct
and shall account to the Seller for such sums as the Seller may direct.

 

		3.	ASSURANCE

 

The parties hereto agree that
they will fully co-operate to do all such further acts and things and execute or sign any further deeds, documents, notices or
confirmations as may be necessary to give full effect to the arrangements contemplated by this Agreement, in particular (but without
limitation) to perfect any assignment and transfer contemplated herein or to effect any registration of rights in any relevant
land registry or to transfer any title which grants the right to immediately enforce a right.

 

		4.	CONSIDERATION

 

The consideration
payable by the Purchaser to the Seller for the assignment of the Loans, the Seller’s interests in the Related Security with
respect to the Loans and all other rights, title, interests and benefits transferred hereunder in respect thereof shall be an amount
equal to the aggregate of:

 

		(a)	the outstanding principal balance of the Loans on the Closing Date; plus

 

		(b)	any accrued and unpaid interest on the Loans up to and including the date immediately preceding
the Closing Date,

 

(the “Purchase
Price”).

 

		5.	CO-OPERATION

 

The Seller shall provide all
reasonable co-operation to the Purchaser during the term of this Agreement and, without prejudice to the generality of the foregoing,
shall upon reasonable notice, permit the Purchaser and its authorised employees and agents and other persons nominated by either
of them, to review its files in relation to the Loans, and any related books of account and records, and the Seller will give promptly
all such information, facilities, explanations and copies of documents relating to the Loans, and all other property, interests,
rights, benefits or obligations hereby agreed to be assigned as any such person may reasonably request; provided, however, that
the Seller shall not be required to deliver and the Purchaser shall not be authorised to review any communications which are subject
to legal professional privilege, internal correspondence, credit analysis or any other information the disclosure of which is prohibited
by law.

 

    	6

    	 

    

		6.	COMPLETION

 

		6.1	Conditions Precedent

 

		(a)	The sale and purchase of the Loans shall be subject to and conditional upon the payment of the
Purchase Price by the Purchaser to the Seller in accordance with Clause 4 (Consideration) in the manner and at the time
agreed between the parties.

 

		(b)	The obligation of the Purchaser to pay the Purchase Price and to purchase the Loans is subject
to and conditional on:

 

		(i)	delivery (or waiver by the Purchaser) of the related obligations on the part of the Seller in Clause
6.3 (Closing Deliverables); and

 

		(ii)	as of the Closing Date, (1) no material part of any Property having been destroyed or damaged or
become subject to any actual or threatened taking by eminent domain or condemnation as determined by Purchaser in its sole discretion,
and (2) no event having occurred or condition existing with respect to the underlying Borrowers or the Loans (whether or not such
event arises to an event of default under the related Loan Agreement) which has an adverse effect on the value or credit quality
of the Loans or the Properties or the creditworthiness of the underlying Borrowers as determined by Purchaser in its sole discretion.

 

		(c)	The Purchaser or the Seller may terminate this Agreement on or prior to the Closing Date if the
conditions set out in Clause 6.1(b) are not satisfied at any time on or prior to the Closing Date or if the Seller notifies the
Purchaser in writing that any of the representations and warranties set out in Schedule 1 (Representations and Warranties)
are not true and correct in respect of the Seller. On or prior to the Closing Date, the Purchaser or the Seller may provide a written
notice to the other party notifying them of the termination of this Agreement in accordance with this Clause 6.1(c) and this Agreement
will terminate with effect from the date specified in such notice. For the avoidance of doubt, any notice of termination can only
be delivered prior to completion of the sale and purchase of the Loans.

 

		(d)	The parties shall use reasonable endeavours to satisfy the conditions for the sale and the purchase
of the Loans on a timely basis.

 

		6.2	Time and Venue

 

Completion of the transfer of
the Loans shall be conditional on completion on the Closing Date and immediately upon satisfaction of the conditions referred to
in Clause 6.1 (Conditions Precedent) above, the steps listed in Clause 6.4 (Completion) below shall take place, and
each of which shall be deemed to take place simultaneously and simultaneously with the satisfaction of the conditions referred
to in Clause 6.1 (Conditions Precedent) above.

 

		6.3	Closing Deliverables

 

On or before
the Closing Date, but prior to the payment of the Purchase Price, the Seller shall deliver, or procure that there is delivered,
to the Purchaser or its representative the items listed in Schedule 2 (Completion Deliverables).

 

		6.4	Completion

 

		(a)	On the Closing Date the Seller shall deliver, or shall cause to be delivered to the Purchaser,
or as it may direct, the Transfer Certificates substantially in the form of the transfer certificates required under the Loan Agreement
duly executed by the Seller together with the schedule required under the terms of the Loan Agreement and the remainder of the
Mortgage File;

 

    	7

    	 

    

		6.5	Payment

 

On the Closing Date, and subject
to the Seller having performed its obligations under Clause 6.3 (Completion), the Purchaser shall procure the remittance
by telegraphic transfer to the account designated by the Purchaser (such account details to be notified to the Purchaser) of the
sum required pursuant to Clause 4 (Consideration) above to be paid to the Seller as consideration for the Loans and the
Seller’s interest in the Related Security with respect to the Loans including all the rights referred to in Clause 2.2 (Terms
of Sale) above, for value on the date agreed between the parties.

 

		7.	WARRANTIES AND REPRESENTATIONS

 

		7.1	Representations and Warranties in Schedule 1

 

The Seller makes the warranties
and representations set forth in Schedule 1 (Representations and Warranties) to the Purchaser as at the Closing Date in
respect of or in relation to the Loans sold pursuant to this Agreement and the Seller’s interest in the Related Security
with respect to the Loans by reference to the facts and circumstances prevailing at the Closing Date.

 

		7.2	Reliance

 

The Seller acknowledges that:

 

		(a)	the warranties and representations set out in Schedule 1 (Representations and Warranties)
and this Clause 7 (Warranties and Representations) given by it are made with a view to inducing the Purchaser in reliance
thereon to enter into this Agreement and the Purchaser has relied and will rely solely upon such warranties and representations
notwithstanding any information in fact possessed or discoverable by the Purchaser or otherwise disclosed to it; and

 

		(b)	prior to entering into this Agreement and prior to the Closing Date, the Purchaser has not made
nor will it have made any enquiries, searches or investigations which a prudent purchaser of similar assets would normally make,
including without limitation, any enquiries or searches of or in respect of the Borrowers and/or the Loans and/or the Related Security
and/or the sums receivable under or in respect of the Loans or the Related Security and/or the terms and conditions of the Loans
and/or the Related Security and/or as to the creditworthiness and/or the suitability of the Borrowers and/or in respect of the
value, title or condition of the Properties and/or the legality, validity and perfection and/or adequacy and/or enforceability
of the Loans and/or the transfer thereof pursuant to this Agreement.

 

		7.3	Further Assurance

 

The Seller undertakes in respect
of the Loans and the Seller’s interest in the Related Security with respect to the Loans, that it will proceed with all due
diligence to do and complete all such acts and things, and execute and sign any necessary deeds, documents, notices or confirmations,
as may be requested by the Purchaser to perfect the title of the Purchaser to the Loans and the Seller’s interest in the
Related Security with respect to the Loans and the other rights in the interest and benefits sold or transferred hereunder.

 

    	8

    	 

    

		7.4	Remedy for Material Breach

 

		(a)	In the event of there being a material breach of any of the representations and warranties of the
Seller contained in Schedule 1 (Representations and Warranties) in relation to any Loan, the Seller shall, within 90 days
of receipt of written notice of such breach from the Purchaser, remedy the matter giving rise to such breach of representation
or warranty if such matter is capable of remedy. If such matter is not capable of remedy or is not so remedied within the said
period of 90 days, the Purchaser may sell and the Seller shall, if required by the Purchaser, repurchase (at the Seller’s
expense) all the rights, title, interest and benefit of the Purchaser in, to and under the relevant Loan and the Seller’s
interest in the Related Security with respect to that Loan as referred to in Clause 2.2 (Terms of Sale) above (the
“Reacquired Assets”) for an aggregate amount equal to the Repurchase Price. Any sale and purchase of Reacquired
Assets pursuant to this Clause 7.4 shall, be effected in such manner as the Seller may agree with the Purchaser including, without
limitation, sub-participation.

 

		(b)	The Seller undertakes to notify the Purchaser in writing (and as soon as practicable upon becoming
aware of the same) of any matter or thing which becomes known to it and which is a breach which is likely to be considered material
in the reasonable opinion of the Purchaser of any of the said representations and warranties which would enable the Purchaser to
exercise its rights under this Clause 7.4.

 

		(c)	The Purchaser will have no other remedy in respect of a material breach as set out in Clause 7.4(a)
above, unless the Seller fails to repurchase the relevant Loan and the Purchaser’s interest in the Related Security in accordance
with this Agreement.

 

		7.5	Completion of any Repurchase

 

		(a)	Completion of any repurchase under Clause 7.4(a) above shall take place not later than 90 days
after receipt by the Seller of written notice of the relevant breach from the Purchaser, when the Seller shall pay to the Purchaser
or as the Purchaser shall direct.

 

		(b)	Any repurchase by the Seller of any Reacquired Assets shall constitute a full discharge and release
of the Seller from any claims which the Purchaser may have against the Seller arising from such breach of representation or warranty
in relation to the Loan and the Related Security.

 

		7.6	Representations of the Seller in relation to itself

 

The Seller hereby represents,
as at the date hereof, to the Purchaser that:

 

		(a)	it is duly incorporated and validly existing as a corporation under the laws of of its country
of incorporation;

 

		(b)	it has full power under its constitutive documents, and all necessary authority has been obtained
and action taken, for it to own its assets, carry on its business as it is now being conducted, and execute, sign, deliver, and
perform the transactions contemplated in this Agreement and this Agreement constitutes the legal, valid and binding obligations
of it;

 

		(c)	neither the Seller nor any person owning more than a 10 per cent. direct or indirect ownership
interest in the Seller is a “Prohibited Person” (as such term is defined in the September 24, 2001 Executive Order
Blocking Property and Prohibiting Transactions With Persons Who Commit, Threaten to Commit, or Support Terrorism) or a person currently
identified on the Specially Designated Nationals and Blocked Persons List maintained by the Office of Foreign Assets Control of
the United States Department of the Treasury (“OFAC”) and/or on any other similar list maintained by OFAC pursuant
to any authorizing statute, executive order or regulation and Seller and each person owning a direct or indirect ownership interest
in the Seller is in full compliance with all applicable orders, rules, regulations and recommendations of OFAC.

 

    	9

    	 

    

		(d)	the signing and delivery of this Agreement does not contravenes or constitute a default under,
or cause to be exceeded any limitation on it or the powers of its directors imposed by or contained in, (i) any law by which it
or any of its assets is bound or affected, (ii) its constitutive documents or (iii) any agreement to which it is a party or by
which any of its assets is bound; and

 

		(e)	it has duly obtained or made each authorisation, approval, consent, licence, exemption or registration
required on its part for or in connection with the execution and performance of each of this Agreement and any matters contemplated
hereby have been unconditionally obtained and are in full force and effect.

 

		8.	NO AGENCY OR PARTNERSHIP

 

It is hereby acknowledged and
agreed by the parties that nothing in this Agreement shall be construed as giving rise to any relationship of agency or partnership
between any of the parties and that in fulfilling its obligations hereunder, each party shall be acting entirely for its own account.

 

		9.	PAYMENTS

 

All payments to be made pursuant
to this Agreement shall be made in sterling in immediately available funds and shall be deemed to be made when they are received
by the payee.

 

		10.	LIABILITY

 

The Purchaser acknowledges to
and agrees with the Seller that:

 

		(a)	no breach of any of, nor any act or omission in respect of, the provisions of Clause 7.1 (Representations
and Warranties in Schedule 1) and the representations and warranties in Schedule 1 (Representations and Warranties)
shall give rise to any claim for damages on the part of the Purchaser against the Seller and the sole remedy of the Purchaser in
respect thereof shall be to take such action under Clause 7.4 (Remedy for Material Breach) as may be available to it and
that no breach of, nor any act or omission in respect of, any warranty or representation other than those representations and warranties
contained in Schedule 1 (Representations and Warranties) shall entitle the Purchaser to require the Seller to repurchase
the Loan sold pursuant to this Agreement and the Seller’s interest in the Related Security with respect to the Loans in accordance
with Clause 7.4 (Remedy for Material Breach) or otherwise, provided that this sub-Clause 10(a) shall not in any way whatsoever
limit the remedies available to the Purchaser (or the exercise thereof) if the Seller, having become bound to repurchase the Loan
sold pursuant to this Agreement and the corresponding interest in the Related Security in accordance with Clause 7.4 (Remedy
for Material Breach), fails to do so; and

 

		(b)	subject and without prejudice to sub-Clause 10(a) above, the Seller shall not have any liability
or responsibility (whether in any case, contractual or tortuous, express or implied) for any loss or damage for or in respect of
any breach of, or any act or omission in respect of, any Obligor’s obligations under the Loan and/or the Seller’s interest
in the Related Security with respect to the Loan or the Seller’s obligations hereunder other than loss or damage directly
(and not indirectly or consequentially) suffered by the Purchaser or the assets of the Purchaser by reason of such breach, act
or omission.

 

		11.	NON PETITION

 

The Seller agrees not to institute
against, or join any other person in instituting against the Purchaser any bankruptcy, reorganization, arrangement, insolvency,
moratorium or liquidation proceedings or other proceedings under U.S. federal or state bankruptcy or similar laws in any jurisdiction
until at least one year and one day. This Clause 11 (Non-Petition) shall survive the termination of this Agreement for any
reason whatsoever.

 

    	10

    	 

    

		12.	WAIVER

 

Any exercise or failure to exercise
any right under this Agreement shall not (unless otherwise herein provided) constitute a waiver of that or any other right.

 

		13.	NOTICES

 

Except as may be otherwise agreed
between the parties, all communications hereunder shall be made in writing to the relevant party by personal delivery or by courier
or first-class registered mail, or the closest local equivalent thereto, or by email or facsimile transmission confirmed by personal
delivery or by courier or first-class registered mail as follows:

 

		To the Seller: 	Jefferies LoanCore (Europe) Limited

 

Jefferies LoanCore (Europe) Limited 

Pinnacle 2 

EastPoint Business Park 

Dublin 3, Ireland

 

		Attention:	Chris Wilson

		Email:	CWilson@loancorecapital.com

 

		To the Purchaser: 	c/o LoanCore Realty Trust, Inc.

 

			55 Railroad Avenue, Suite 100

 

			Greenwich, CT 06830

 

		Attention:	Jordan Bock

 

		Telephone Number: 	(203) 861-6065

 

		Facsimile Number: 	(203) 861-6006

 

or to such other address, telephone
number or facsimile number as either party may notify to the other in accordance with the terms hereof from time to time. Any communications
hereunder shall be effective upon receipt.

 

		14.	VARIATIONS

 

This Agreement may only be varied
in writing signed by duly authorised signatories on behalf of the parties hereto.

 

    	11

    	 

    

		15.	COUNTERPARTS

 

This Agreement may be executed
(manually or electronically) in one or more counterparts, and each such counterpart (when executed) shall be an original. Such
counterparts shall together constitute one and the same instrument.

 

		16.	GOVERNING LAW AND JURISDICTION

 

		16.1	This Agreement and any non-contractual obligations arising out of or in connection with it shall
be governed by and construed in accordance with the laws of England.

 

		16.2	Subject as provided below, each party hereto hereby agrees for the benefit of the other parties
that the courts of England are to have jurisdiction to settle any disputes which may arise out of or in connection with this Agreement
and that accordingly any suit, action or proceedings (together referred to as “Proceedings”) arising out of or
in connection with this Agreement may be brought in such courts.

 

		16.3	Subject as provided below, the Purchaser and the Seller irrevocably submit to the jurisdiction
of such courts and waive any objection to any Proceedings in respect of the Agreement in such courts whether on the ground of venue
or on the ground that the Proceedings have been brought in an inconvenient forum.

 

		16.4	The Purchaser irrevocably appoints Law Debenture Corporate Services Limited of Fifth Floor, 100
Wood Street, London EC2V 7EX as its agent for service of process in respect of any Proceedings in England.

 

		16.5	Each of the Purchaser and the Seller irrevocably submits to the jurisdiction of such courts and
waives any objection to any Proceedings in respect of the Agreement in such courts whether on the ground of venue or on the ground
that the Proceedings have been brought in an inconvenient forum.

 

IN WITNESS whereof
the parties hereto have executed this Agreement on the day and year first before written.

 

    	12

    	 

    

SCHEDULE 1

REPRESENTATIONS AND WARRANTIES

 

		(a)	The Loans carry a right to repayment of principal in an amount not less than the Purchase Price
paid or deemed paid for the Loans by the Purchaser based on its principal amount outstanding on the Closing Date.

 

		(b)	Interest is charged on each Loan at such a rate as may be determined in accordance with the provisions
of the relevant Loan Agreement.

 

		(c)	Pursuant to the terms of the Loan Agreements, the Borrowers are not entitled to exercise any right
of set-off (except to the extent provided by law or in the Loan Agreement) against the Seller under the Loan Agreement in respect
of any amount that is payable under the Loan Agreement.

 

		(d)	With the exception of a further commitment of £545,000 in relation to the Neptune Loan which
is the only future funding obligation under the Loan Agreements and which commitment shall be assumed by the Purchaser, the Loan
Agreements contain no obligation to make any further advances which remains to be performed by the Seller on the Closing Date and
no part of any advance pursuant to the Loans has been retained by the Seller pending compliance by the Borrowers or any other party
with any other conditions.

 

		(e)	The Seller or the Borrower Facility Agent has, since the origination of the Loans, kept full and
proper accounts, books and records showing clearly all transactions, payments, receipts, proceedings and notices relating to the
Neptune Loan and the PBN Whole Loan and which are complete and accurate in all material respects; all such accounts, books and
records are up to date and are held by, or to the order of, the Seller or, as the case may be, the Borrower Facility Agent and,
subject to completion of any registration or recording which may be pending, the documents of title relating to the Properties
and the Seller’s files are in the possession of or held to the order of the Borrower Security Trustee.

 

		(f)	The Properties are situated in the United Kingdom.

 

		(g)	In relation to the Properties, the Borrowers or Property Owners had, as at the date upon which
the relevant advance was made or of the acquisition, subject to the matters disclosed during the course of the due diligence carried
out in connection with the origination or acquisition of the Loans, a good and marketable title to the Properties.

 

		(h)	In relation to the Properties, the title of the Borrowers or Property Owners to the Properties
has been registered at the relevant land registry.

 

		(i)	The Property Owners were the sole legal and beneficial owners of the Properties free (save for
the Related Security and save for any encumbrance which (i) was taken into account at the time the relevant Loan was made, or (ii)
is postponed to and ranks in priority behind the Related Security by virtue of a deed of priority or postponement or ranking agreement
or (iii) as created, ranked in point of priority behind the Related Security) from any encumbrance which would materially adversely
affect such title or the value for mortgage purposes set out in the valuation referred to in paragraph (t) below (including any
encumbrance contained in any agreement for lease, occupational lease or licence or other right of occupation or right to receive
rent to which the Properties may be subject from time to time (an “Occupational Lease”) or any similar document
relevant to the Properties).

 

		(j)	The Seller is not aware (from any information received by it in the course of administering the
Neptune Loan and the PBN Whole Loan without further inquiry) of any circumstances giving rise to a material reduction in the value
of the Properties since the funding or acquisition date of the Neptune Loan and the PBN Whole Loan other than market forces affecting
the values of the properties comparable to the Properties in the area where it is located.

 

    	13

    	 

    

		(k)	Each Loan constitutes a valid and binding obligation of, and is enforceable against, the Borrowers,
subject to general principles of law limiting the same, as set out in the legal opinions referred to in the Loan Agreement.

 

		(l)	Subject, in the case of Mortgages required to be registered or recorded at the relevant land registry,
to such registration or recording, each Mortgage is a legal, valid and subsisting first ranking fully perfected security interest
on the Property to which it relates and constitutes a legal, valid and binding obligation of, and is enforceable against the Borrowers
or Property Owners, subject to general principles of law limiting the same, as set out in the legal opinions referred to in the
Loan Agreement. Where registration at the Land Registry is required all necessary priority period protective searches have been
carried out and the application to register such security interest has been or is in the process of being made to the proper office
within the priority period in the required form accompanied by the prescribed registration fee.

 

		(m)	The Seller is the sole legal and beneficial owner of the Loans and is the sole beneficial owner
of the Related Security in relation to the Loans, free and clear of all encumbrances, claims and equities and subject to the interests
of the other creditors as governed by the Intercreditor Deed and, in relation to the PBN B2 Note Loan, the PBN B Note Intercreditor
Deed.

 

		(n)	The Borrower Security Trustee or Seller is the sole legal owner of the Mortgages (subject to necessary
registration and recordings), subject to the trust declared by the Borrower Security Trustee over its interest in the Mortgages,
free and clear of all encumbrances, overriding interests (other than those to which the Properties are subject), claims and equities
(including without limitation, rights of set-off or counterclaim) and there were at the time of completion of the Mortgages or
acquisition of the Loan relating to the Mortgages, no adverse entries of encumbrances or other such claims or equities or applications
for adverse entries of encumbrances, claims or equities against any title registered at the relevant land registry or registered
at any other registry on which entries would rank prior to the Borrower Security Trustee’s or the Seller’s interests in the Mortgages.

 

		(o)	The legal and beneficial right, title and interest of the Seller in the Loan and the related interest
in the Related Security may be assigned absolutely, or as the case may be, by operation of law or pursuant to the Loan Sale Agreement,
to the Purchaser and such transfer does not violate any provision of the Loan Agreement.

 

		(p)	Prior to the advancing of the Neptune Loan and the PBN Whole Loan and the granting of any Related
Security in each case: (i) the Seller commissioned a due diligence procedure which initially or after further investigation disclosed
nothing which caused it to decline to proceed with the advance on its agreed terms; and (ii) the Seller was not aware of any matter
or thing affecting the title of the Borrowers or Property Owners to any part of the Related Security which caused it to decline
to proceed with the advance on its agreed terms.

 

		(q)	To the best of the Seller’s knowledge (having made no investigation in respect thereof) no report
on title given by a lawyer in connection with its origination of the Mortgages, any Related Security and the Neptune Loan or the
PBN Whole Loan was negligently or fraudulently prepared by the relevant lawyer.

 

		(r)	The Properties securing the Neptune Loan and the PBN Whole Loan were valued by a qualified surveyor
or valuer appointed by the Seller and independent from the Seller.

 

		(s)	To the best of the Seller’s knowledge, as a commercial property lender and not, for the avoidance
of doubt, as a valuer and having made no enquiries in relation thereto, each Original Valuation given in connection with the Neptune
Loan and the PBN Whole Loan was not fraudulently undertaken by the related valuer and to the best of the Seller’s knowledge (as
a commercial property lender only and not, for the avoidance of doubt, as a valuer) such Original Valuation did not disclose any
fact or circumstance that if disclosed would have caused the Seller to decline to proceed with its origination of the Neptune Loan
or, as applicable the PBN Whole Loan.

 

    	14

    	 

    

		(t)	To the best of the Seller’s knowledge after using reasonable endeavours to ensure the same: (i)
with regard to the Properties securing the Neptune Loan and the PBN Whole Loan, the Properties are covered by insurance on the
Properties and plant and machinery (including fixtures and improvements); (ii) third party liability insurance is in place; and
(iii) the relevant insurance policy for the Properties which are commercial properties provides cover in respect of three years’
loss of rent with respect to such commercial Properties.

 

		(u)	The Seller has not received and (insofar as the Seller is aware) neither the Borrower Facility
Agent nor the Borrower Security Trustee has received written notice that any insurance policy is about to lapse on account of failure
by the relevant entity maintaining such insurance to pay the relevant premiums.

 

		(v)	Prior to the date of the origination of the Neptune Loan and the PBN Whole Loan, to the best of
the Seller’s knowledge, each of the Neptune Loan and the PBN Whole Loan and any relevant Related Security and the circumstances
of the Borrowers satisfied in all material respects the lending criteria of the Seller.

 

		(w)	The Seller has not received written notice and the Seller is not aware of (without having made
any specific enquiries) the bankruptcy, liquidation, receivership, administration, examinership or a winding up or administrative
order or dissolution made against the Borrowers or Property Owner.

 

		(x)	The particulars of the Mortgages and other elements of the Related Security have been registered
and perfected (or will be registered and perfected with respect to those Mortgages where registration or recording is pending at
the relevant land registry) in a manner compliant with English or other applicable law.

 

		(y)	Since the date of origination of the Neptune Loan and the PBN Whole Loan, no amount of principal
or interest due from the Borrowers has at any time been more than 14 days overdue as at the Closing Date.

 

		(z)	The Seller is not aware of any material default, material breach or material violation under any
Loan Agreement or any Mortgage or the Related Security which has not been remedied, cured or waived or of any outstanding material
default, material breach or material violation by the relevant Borrowers under any Mortgage, the Related Security or the Neptune
Loan and the PBN Whole Loan or of any outstanding event which with the giving of notice, the expiration of any applicable grace
period or making of any determination, would constitute such a default, breach or violation.

 

		(aa)	The Seller has performed in all material aspects all of its obligations under or in connection
with the Loans and so far as the Seller is aware none of the Borrowers has taken or threatened to take any action against the Seller,
the Borrower Facility Agent or the Borrower Security Trustee for any material failure on the part of the Seller, the Borrower Facility
Agent or the Borrower Security Trustee under the Loans or Related Security to perform any such obligations.

 

		(bb)	The Seller is not aware of any litigation or claim calling into question in any material way the
Seller’s or the Borrower Security Trustee’s title to the Loans, its Related Security or the Mortgages.

 

		(cc)	Neither the Seller nor (so far as the Seller is aware) the Borrower Facility Agent or the Borrower
Security Trustee received written notice of any default or forfeiture or irritancy of any Occupational Lease granted in respect
of the Properties or of the insolvency of any tenant of the Properties which would, in any case, render the Properties unacceptable
as security for the Neptune Loan or the PBN Whole Loan (as applicable) in the context of the applicable lending criteria.

 

		(dd)	Prior to making the initial advance under the Neptune Loan and the PBN Whole Loan, (i) no express
recommendation was received by the Seller from a qualified surveyor or valuer to carry out any environmental audit, survey or report
of the Properties which was not pursued, unless otherwise determined by the Seller to not be necessary to perform prior to such
origination or acquisition, and (ii) if any such environmental audit, survey or report was performed prior to such origination
or acquisition, the results of any such environmental audit, survey or report which was procured by the Seller would have been
taken into account in the Original Valuation.

 

    	15

    	 

    

SCHEDULE 2

COMPLETION DELIVERABLES

 

		1.	Each Transfer Certificate duly executed by the parties thereto.

 

		2.	A duly executed accession deed for the accession of the Purchaser to the Intercreditor Deed in
the form prescribed under the Intercreditor Deed.

 

		3.	A duly executed accession deed for the accession of the Purchaser to the PBN B Note Intercreditor
Deed in the form prescribed under the PBN B Note Intercreditor Deed.

 

		4.	All necessary consents under the Loan Agreements, the Intercreditor Deed and the PBN B Note Intercreditor
Deed in order to effect the terms of this Agreement.

 

		5.	A servicing tape from the Borrower Facility Agent reflecting the current escrow and reserve funds
actually on deposit on the Closing Date with respect to each Loan.

 

		6.	Receipt by the Purchaser of a certificate from the Custodian to the effect that the Custodian is
holding the Mortgage File for each Loan, substantially in the form required by the related custodial agreement.

 

		7.	The Purchaser having provided such documentation or evidence as may be requested by the Seller
or any services provider of the Seller in order for the Seller, or for any such services provider of the Seller, to carry out and
be satisfied that it has complied with all necessary identifications checks or other similar checks to meet its obligations under
any applicable law in relation to the receipt of the funds representing the Purchase Price.

 

    	16

    	 

    

SIGNATURES

 

	JEFFERIES LOANCORE (EUROPE) LIMITED

(as Seller)	 
	 	 	 
	 	 	 
	By:	 	 
	 	Name:	 
	 	Title:	 
	 	 	 
	 	 	 
	By:	 	 
	 	Name:	 
	 	Title:	 

 

 

 

[Signature Page to Loan Sale Agreement]

 

    	17

    	 

    

	LCRT HOLDINGS LLC	 
	 	 	 
	(as Purchaser)	 
	 	 	 
	 	 	 
	By:	 	 
	 	Name:	 
	 	Title:	 

 

 

 

[Signature Page to Loan Sale Agreement]

 

    	18SHARE
EXCHANGE AGREEMENT

 

Dated

 

June
22, 2015

 

by
and among

 

QUINT
MEDIA, INC., a Nevada Corporation

as
the Acquiror and Parent.

 

and

 

ONCBIOMUNE,
INC.,

a
Louisiana corporation

 

and

 

THE
SHAREHOLDERS OF

 

ONCBIOMUNE,
INC.

 

    	 

    	 

    

 

TABLE
OF CONTENTS

 

	 	 	PAGE
	ARTICLE
    I REPRESENTATIONS, COVENANTS, AND WARRANTIES OF ONC AND THE SHAREHOLDERS 	1
	 	Section 1.01 Incorporation.
    	1
	 	Section 1.02 Authorized
    Shares and Capital. 	1
	 	Section 1.03 Subsidiaries
    and Predecessor Corporations 	2
	 	Section 1.04 Financial
    Statements. 	2
	 	Section 1.05 Information
    	2
	 	Section 1.06 Options
    or Warrants 	3
	 	Section 1.07 Absence
    of Certain Changes or Events 	3
	 	Section 1.08 Litigation
    and Proceedings 	3
	 	Section 1.09 Contracts.
    	3
	 	Section 1.10 Compliance
    With Laws and Regulations 	4
	 	Section 1.11 Approval
    of Agreement 	4
	 	Section 1.12 ONC
    Schedules 	4
	 	Section 1.13 Valid
    Obligation 	4
	 	Section 1.14 Investment
    Representations 	4
	 	 	
	ARTICLE
    II REPRESENTATIONS, COVENANTS, AND WARRANTIES OF THE COMPANY 	6
	 	Section 2.01 Organization
    	6
	 	Section 2.02 Capitalization
    	7
	 	Section 2.03 Subsidiaries
    and Predecessor Corporations 	7
	 	Section 2.04 OTC
    Reports. 	7
	 	Section 2.05 Information
    	7
	 	Section 2.06 Options
    or Warrants 	8
	 	Section 2.07 Absence
    of Certain Changes or Events 	8
	 	Section 2.08 Litigation
    and Proceedings 	9
	 	Section 2.09 Contracts.
    	9
	 	Section 2.10 No
    Conflict With Other Instruments 	9
	 	Section 2.11 Compliance
    With Laws and Regulations 	9
	 	Section 2.12 Approval
    of Agreement 	9
	 	Section 2.13 Material
    Transactions or Affiliations 	9
	 	Section 2.14 The
    Company Schedules 	10
	 	Section 2.15 Valid
    Obligation. 	10
	 	Section 2.16 OTC
    Marketplace Quotation. 	10
	 	 	
	ARTICLE
    III SHARE EXCHANGE 	10
	 	Section 3.01 The
    Exchange and Share Cancellation. 	10
	 	Section 3.02 Closing
    	11
	 	Section 3.03 Closing
    Events 	11
	 	Section 3.04 Termination
    	11
	ARTICLE
    IV SPECIAL COVENANTS 	11
	 	Section 4.01 Access
    to Properties and Records 	11
	 	Section 4.02 Delivery
    of Books and Records 	11
	 	Section 4.03 Third
    Party Consents and Certificates 	12
	 	Section 4.04 Actions
    Prior to Closing 	12

 

    	 

    	 

    

 

	ARTICLE
    V CONDITIONS PRECEDENT TO OBLIGATIONS OF THE COMPANY 	12
	 	Section 5.01 Accuracy
    of Representations and Performance of Covenants 	12
	 	Section 5.02 Officer’s
    Certificate 	13
	 	Section 5.03 Good
    Standing 	13
	 	The
    Company shall have received a certificate of good standing from the Secretary of State of Louisiana or other appropriate office,
    dated as of a date within ten days prior to the Closing Date certifying that ONC is in good standing as a corporation in the
    State of Florida.	13
	 	Section 5.04 Minimum
    ONC Shareholders 	13
	 	Section 5.05 No
    Governmental Prohibition 	13
	 	Section 5.06 Consents
    	13
	 	Section 5.07 Other
    Items. 	13
	 	 	
	ARTICLE
    VI CONDITIONS PRECEDENT TO OBLIGATIONS OF ONC AND THE ONC SHAREHOLDERS 	13
	 	Section 6.01 Accuracy
    of Representations and Performance of Covenants 	13
	 	Section 6.02 Officer’s
    Certificate 	14
	 	Section 6.03 Good
    Standing 	14
	 	Section 6.04 No
    Governmental Prohibition 	14
	 	Section 6.05 Approval
    by the Company Board of Directors 	14
	 	Section 6.06 Consents
    	14
	 	Section 6.07 Shareholder
    Report 	14
	 	Section 6.08 Other
    Items. 	14
	 	 	
	ARTICLE
    VII MISCELLANEOUS 	15
	 	Section 7.01 Brokers
    	15
	 	Section 7.02 Governing
    Law 	15
	 	Section 7.03 Notices
    	15
	 	Section 7.04 Attorney’s
    Fees 	15
	 	Section 7.05 Confidentiality
    	15
	 	Section 7.06 Public
    Announcements and Filings 	16
	 	Section 7.07 Schedules;
    Knowledge 	16
	 	Section 7.08 Third
    Party Beneficiaries 	16
	 	Section 7.09 Expenses
    	16
	 	Section 7.10 Entire
    Agreement 	16
	 	Section 7.11 Survival;
    Termination 	16
	 	Section 7.12 Counterparts
    	16
	 	Section 7.13 Amendment
    or Waiver 	16
	 	Section 7.14 Best
    Efforts 	16

 

EXHIBITS

 

Exhibit
A – Shareholders’ Signature Pages

 

Exhibit
B – Form of Amended and Restated Articles of Incorporation

 

    	 

    	 

    

 

SHARE
EXCHANGE AGREEMENT

 

THIS
SHARE EXCHANGE AGREEMENT (hereinafter referred to as this “Agreement”) is entered into as of this 22nd day of June
2015, by and between QUINT MEDIA, INC., a Nevada corporation (the “Company”), with offices at 330 Clematis Street,
Suite 217, West Palm Beach, Florida 33401 and ONCBIOMUNE, INC., a Louisiana corporation (“ONC”), with offices at 17050
Medical Center Drive, Baton Rouge, Louisiana 70816 and the shareholders of ONC set forth on Composite Exhibit A (the “ONC
Shareholders”), upon the following premises:

 

Premises

 

WHEREAS,
the Company is a publicly held corporation organized under the laws of the State of Nevada;

 

WHEREAS,
ONC is a privately-held company organized under the laws of Louisiana;

 

WHEREAS,
the Company agrees to acquire up to forty-seven million (47,000,000) (“ONC Shares”) of the issued and outstanding
common shares of ONC representing 100% of ONC’s issued and outstanding common stock from the ONC Shareholders in exchange
for the issuance of one share of the Company’s Common Stock and .0212765957446809 of the Company’s Series A Preferred
Stock for each share of ONC’s common stock (“Exchange Ratio”) (the “Exchange”) after giving effect
to the Reverse Stock Split and other transactions provided for in this Agreement. On the Closing Date, the ONC Shareholders will
become shareholders of the Company and ONC will become a subsidiary of the Company. Immediately after the share exchange and a
Reverse Stock Split, there will 50,000,000 shares of the Company’s common stock outstanding with 47,000,000 or 94% thereof
owned by the ONC Shareholders and 1,000,000 shares of the Company’s Series A Preferred Stock with 100% thereof owned by
the ONC Shareholders.

 

WHEREAS,
for Federal income tax purposes, it is intended that the Exchange qualify as a reorganization under the provisions of Section
368(a) of the Internal Revenue Code of 1986, as amended (the “Code”); and

 

Agreement

 

NOW
THEREFORE, on the stated premises and for and in consideration of the mutual covenants and agreements hereinafter set forth and
the mutual benefits to the parties to be derived herefrom, and intending to be legally bound hereby, it is hereby agreed as follows:

 

ARTICLE
I

REPRESENTATIONS, COVENANTS, AND WARRANTIES OF ONC AND THE SHAREHOLDERS

 

As
an inducement to, and to obtain the reliance of the Company, except as set forth in the ONC Schedules (as hereinafter defined),
ONC represents and warrants to the Company that as of the date hereof and the Closing Date (as hereinafter defined), as follows:

 

Section
1.01 Incorporation. ONC is a company duly organized, validly existing, and in good standing under the laws of Louisiana
and has the corporate power and is duly authorized under all applicable laws, regulations, ordinances, and orders of public authorities
to carry on its business in all material respects as it is now being conducted. Included in the ONC Schedules is a complete and
correct copy of the Articles of incorporation of ONC as in effect on the date hereof. The execution and delivery of this Agreement
does not, and the consummation of the transactions contemplated hereby will not, violate any provision of ONC’s Articles
of incorporation. ONC has taken all actions required by law, its Articles of Incorporation, or otherwise to authorize the execution,
delivery and performance of this Agreement. ONC has full power, authority, and legal capacity and has taken all action required
by law, it’s Articles of Incorporation, and otherwise to consummate the transactions herein contemplated.

 

Section
1.02 Authorized Shares and Capital. The authorized number of common shares with $0.0001 par value of ONC is forty-seven
million (47,000,000) with all 47,000,000 shares issued and outstanding. The issued and outstanding shares are validly issued,
fully paid, and non-assessable and not issued in violation of the preemptive or other rights of any person.

 

    	 

    	 

    

 Share
                                         Exchange Agreement

Quint
Media, Inc,/OncBioMune, Inc.

 

Section
1.03 Subsidiaries and Predecessor Corporations. Other than OncBioMune, LLC, a Louisiana limited liability company, ONC
does not have any predecessor corporation(s), no subsidiaries, and does not own, beneficially or of record, any shares of any
other corporation.

 

Section
1.04 Financial Statements.

 

(a)
Within five days of execution of this agreement, ONC shall provide the Company with ONC’s (i) balance sheet as of December
31, 2014, and the related statements of operations, stockholders’ equity and cash flows for the period ended December 31,
2014 prepared in accordance with GAAP and audited by a PCAOB independent auditor (the “ONC Financial Statements”).

 

(b)
Within five days of execution of this agreement, ONC shall provide the Company with ONC’s (i) balance sheet as of March
31, 2015, and the related statements of operations, stockholders’ equity and cash flows for the period ended March 31, 2015
prepared in accordance with GAAP and reviewed, but not audited, by a PCAOB independent auditor (the “ONC Financial Statements”).

 

(c)
All such financial statements shall be prepared in accordance with generally accepted accounting principles consistently applied
throughout the periods involved. The ONC balance sheets shall be true and accurate and present fairly as of their respective dates
the financial condition of ONC. As of the date of such balance sheets, except as and to the extent reflected or reserved against
therein, ONC shall have no liabilities or obligations (absolute or contingent) which should be reflected in the balance sheets
or the notes thereto prepared in accordance with generally accepted accounting principles, and all assets reflected therein will
be properly reported and present fairly the value of the assets of ONC, in accordance with generally accepted accounting principles.
The statements of operations, stockholders’ equity and cash flows will reflect fairly the information required to be set
forth therein by generally accepted accounting principles.

 

(d)
ONC has duly and punctually paid all Governmental fees and taxes which it has become liable to pay and has duly allowed for all
taxes reasonably foreseeable and is under no liability to pay any penalty or interest in connection with any claim for governmental
fees or taxes and ONC has made any and all proper declarations and returns for tax purposes and all information contained in such
declarations and returns is true and complete and full provision or reserves have been made in its financial statements for all
Governmental fees and taxes.

 

(e)
The books and records, financial and otherwise, of ONC are in all material aspects complete and correct and have been maintained
in accordance with good business and accounting practices.

 

(f)
All of ONC’s assets are reflected on its financial statements, and, except as set forth in the ONC Schedules or the financial
statements of ONC or the notes thereto, ONC has no material liabilities, direct or indirect, matured or unmatured, contingent
or otherwise.

 

Section
1.05 Information. The information concerning ONC set forth in this Agreement and in the ONC Schedules is complete and accurate
in all material respects and does not contain any untrue statement of a material fact or omit to state a material fact required
to make the statements made, in light of the circumstances under which they were made, not misleading. In addition, ONC has fully
disclosed in writing to the Company (through this Agreement or the ONC Schedules) all information relating to matters involving
ONC or its assets or its present or past operations or activities which (i) indicated or may indicate, in the aggregate, the existence
of a greater than $10,000 liability, (ii) have led or may lead to a competitive disadvantage on the part of ONC or (iii) either
alone or in aggregation with other information covered by this Section, otherwise have led or may lead to a material adverse effect
on ONC, its assets, or its operations or activities as presently conducted or as contemplated to be conducted after the Closing
Date, including, but not limited to, information relating to governmental, employee, environmental, litigation and securities
matters and transactions with affiliates.

 

    	- 2 -

    	 	 	 

    

 

Share
Exchange Agreement

Quint
Media, Inc,/OncBioMune, Inc.

 

Section
1.06 Options or Warrants. Except as disclosed on ONC Schedule 1.06, there are no existing options, warrants, calls, or
commitments of any character relating to the authorized and unissued stock of ONC.

 

Section
1.07 Absence of Certain Changes or Events. Except as disclosed on ONC Schedule 1.07, since March 31, 2015 or such other
date as provided for herein:

 

(a)
there has not been any material adverse change in the business, operations, properties, assets, or condition (financial or otherwise)
of ONC;

 

(b)
ONC has not (i) amended its Articles of Incorporation since formation; (ii) declared or made, or agreed to declare or make, any
payment of dividends or distributions of any assets of any kind whatsoever to stockholders or purchased or redeemed, or agreed
to purchase or redeem, any of its shares; (iii) made any material change in its method of management, operation or accounting,
(iv) entered into any other material transaction other than sales in the ordinary course of its business; or (v) made any increase
in or adoption of any profit sharing, bonus, deferred compensation, insurance, pension, retirement, or other employee benefit
plan, payment, or arrangement made to, for, or with its officers, directors, or employees; and

 

(c)
ONC has not (i) granted or agreed to grant any options, warrants or other rights for its stocks, bonds or other corporate securities
calling for the issuance thereof, (ii) borrowed or agreed to borrow any funds or incurred, or become subject to, any material
obligation or liability (absolute or contingent) except as disclosed herein and except liabilities incurred in the ordinary course
of business; (iii) sold or transferred, or agreed to sell or transfer, any of its assets, properties, or rights or canceled, or
agreed to cancel, any debts or claims; or (iv) issued, delivered, or agreed to issue or deliver any stock, bonds or other corporate
securities including debentures (whether authorized and unissued or held as treasury stock) except in connection with this Agreement.

 

Section
1.08 Litigation and Proceedings. Except as disclosed on ONC Schedule 1.08, there are no actions, suits, proceedings, or
investigations pending or, to the knowledge of ONC after reasonable investigation, threatened by or against ONC or affecting ONC
or its properties, at law or in equity, before any court or other governmental agency or instrumentality, domestic or foreign,
or before any arbitrator of any kind. ONC does not have any knowledge of any material default on its part with respect to any
judgment, order, injunction, decree, award, rule, or regulation of any court, arbitrator, or governmental agency or instrumentality
or of any circumstances which, after reasonable investigation, would result in the discovery of such a default.

 

Section
1.09 Contracts.

 

(a)
All “material” contracts, agreements, franchises, license agreements, debt instruments or other commitments to which
ONC is a party or by which it or any of its assets, products, technology, or properties are bound other than those incurred in
the ordinary course of business have been previously disclosed to the Company or the ONC Shareholders. A “material”
contract, agreement, franchise, license agreement, debt instrument or commitment is one which (i) will remain in effect for more
than six (6) months after the date of this Agreement or (ii) involves aggregate obligations of at least ten thousand dollars ($10,000);

 

(b)
All contracts, agreements, franchises, license agreements, and other commitments to which ONC is a party or by which its properties
are bound and which are material to the operations of ONC taken as a whole are valid and enforceable by ONC in all respects, except
as limited by bankruptcy and insolvency laws and by other laws affecting the rights of creditors generally; and

 

    	- 3 -

    	 	 	 

    

 

Share
Exchange Agreement

Quint
Media, Inc,/OncBioMune, Inc.

 

(c)
Except as previously disclosed to the Company or the ONC Shareholders or reflected in the most recent ONC balance sheet, ONC is
not a party to any oral or written (i) contract for the employment of any officer or employee; (ii) profit sharing, bonus, deferred
compensation, stock option, severance pay, pension benefit or retirement plan, (iii) agreement, contract, or indenture relating
to the borrowing of money, (iv) guaranty of any obligation; (vi) collective bargaining agreement; or (vii) agreement with any
present or former officer or director of ONC.

 

Section
1.10 Compliance With Laws and Regulations. To the best of its knowledge, ONC has complied with all applicable statutes
and regulations of any federal, state, or other governmental entity or agency thereof, except to the extent that noncompliance
would not materially and adversely affect the business, operations, properties, assets, or condition of ONC or except to the extent
that noncompliance would not result in the occurrence of any material liability for ONC.

 

Section
1.11 Approval of Agreement. This Agreement has been duly and validly authorized and executed and delivered on behalf of
ONC and the ONC Shareholders and this Agreement constitutes a valid and binding agreement of ONC and the ONC Shareholders enforceable
in accordance with its terms.

 

Section
1.12 ONC Schedules. ONC has delivered to the Company the following schedules, which are collectively referred to as the
“ONC Schedules” and which consist of separate schedules dated as of the date of execution of this Agreement, all certified
by the President of ONC as complete, true, and correct as of the date of this Agreement in all material respects:

 

(a)
a schedule containing complete and correct copies of the Articles of Incorporation of ONC and the Bylaws, each as in effect as
of the date of this Agreement;

 

(b)
a schedule containing the financial statements of ONC identified in paragraph 1.04(a);

 

(c)
a schedule setting forth any information, together with any required copies of documents, required to be disclosed in the Company
Schedules by Sections 1.01 through 1.11.

 

ONC
shall cause the ONC Schedules and the instruments and data delivered to the Company hereunder to be promptly updated after the
date hereof up to and including the Closing Date.

 

Section
1.13 Valid Obligation. This Agreement and all agreements and other documents executed by ONC in connection herewith constitute
the valid and binding obligations of ONC, enforceable in accordance with its or their terms, except as may be limited by bankruptcy,
insolvency, moratorium or other similar laws affecting the enforcement of creditors’ rights generally and subject to the
qualification that the availability of equitable remedies is subject to the discretion of the court before which any proceeding
therefore may be brought.

 

Section
1.14 Investment Representations

 

(a)
Investment Purpose. As of the date hereof, the ONC Shareholders understand and agree that the consummation of this Agreement
including the delivery of the Exchange Consideration (as hereinafter defined) to the ONC Shareholders in exchange for the Securities
as contemplated hereby constitutes the offer and sale of securities under the Securities Act of 1933, as amended (the “Securities
Act “) and applicable state statutes and that the Securities are being acquired for the ONC Shareholders’ own account
and not with a present view towards the public sale or distribution thereof, except pursuant to sales registered or exempted from
registration under the Securities Act; provided, however, that by making the representations herein, the ONC Shareholders
do not agree to hold any of the Exchange Consideration for any minimum or other specific term and reserves the right to dispose
of the Exchange Consideration at any time in accordance with or pursuant to a registration statement or an exemption under the
Securities Act.

 

    	- 4 -

    	 	 	 

    

 

Share
Exchange Agreement

Quint
Media, Inc,/OncBioMune, Inc.

 

(b)
Investor Status. Each of the ONC Shareholders is either an “accredited investor” as that term is defined in
Rule 501(a) of Regulation D (an “Accredited Investor”) or a sophisticated investor who has such knowledge and experience
in financial and business matters to be capable of evaluating the merits and risks of this Agreement and the underlying transactions.
Each ONC Shareholder has been furnished with all documents and materials relating to the business, finances and operations of
the Company and its subsidiaries and information that such ONC Shareholder requested and deemed material to making an informed
decision regarding this Agreement and the underlying transactions

 

(c)
Reliance on Exemptions. Each of the ONC Shareholders understands that the Exchange Consideration is being offered and sold
to the ONC Shareholders in reliance upon specific exemptions from the registration requirements of United States federal and state
securities laws and that the Company is relying upon the truth and accuracy of, and the ONC Shareholders’ compliance with,
the representations, warranties, agreements, acknowledgments and understandings of the ONC Shareholders set forth herein in order
to determine the availability of such exemptions and the eligibility of the ONC Shareholders to acquire the Exchange Consideration.

 

(d)
Information. The ONC Shareholders and its advisors, if any, have been furnished with all materials relating to the business,
finances and operations of the Company and materials relating to the offer and sale of the Exchange Consideration which have been
requested by the ONC Shareholders or its advisors. The ONC Shareholders and its advisors, if any, have been afforded the opportunity
to ask questions of the Company. Notwithstanding the foregoing, the Company has not disclosed to the ONC Shareholders any material
nonpublic information and will not disclose such information unless such information is disclosed to the public prior to or promptly
following such disclosure to the ONC Shareholders. The ONC Shareholders understands that its investment in the Exchange Consideration
involves a significant degree of risk. The ONC Shareholders is not aware of any facts that may constitute a breach of any of the
Company’s representations and warranties made herein.

 

(e)
Governmental Review. Each of the ONC Shareholders understands that no United States federal or state agency or any other
government or governmental agency has passed upon or made any recommendation or endorsement of the Exchange Consideration.

 

(f)
Transfer or Re-sale. Each of the ONC Shareholders understands that (i) the sale or re-sale of the Exchange Consideration
has not been and is not being registered under the Securities Act or any applicable state securities laws, and the Exchange Consideration
may not be transferred unless (a) the Exchange Consideration is sold pursuant to an effective registration statement under the
Securities Act, (b) the ONC Shareholders shall have delivered to the Company, at the cost of the ONC Shareholders, an opinion
of counsel that shall be in form, substance and scope customary for opinions of counsel in comparable transactions to the effect
that the Exchange Consideration to be sold or transferred may be sold or transferred pursuant to an exemption from such registration,
which opinion shall be accepted by the Company, (c) the Exchange Consideration is sold or transferred to an “affiliate”
(as defined in Rule 144 promulgated under the Securities Act (or a successor rule) (“Rule 144”)) of the ONC Shareholders
who agree to sell or otherwise transfer the Exchange Consideration only in accordance with this Section and who is an Accredited
Investor, (d) the Exchange Consideration is sold pursuant to Rule 144, or (e) the Exchange Consideration is sold pursuant to Regulation
S under the Securities Act (or a successor rule) (“Regulation S”), and the ONC Shareholders shall have delivered to
the Company, at the cost of the ONC Shareholders, an opinion of counsel that shall be in form, substance and scope customary for
opinions of counsel in corporate transactions, which opinion shall be accepted by the Company; (ii) any sale of such Exchange
Consideration made in reliance on Rule 144 may be made only in accordance with the terms of said Rule and further, if said Rule
is not applicable, any re-sale of such Exchange Consideration under circumstances in which the seller (or the person through whom
the sale is made) may be deemed to be an underwriter (as that term is defined in the Securities Act) may require compliance with
some other exemption under the Securities Act or the rules and regulations of the SEC thereunder; and (iii) neither the Company
nor any other person is under any obligation to register such Exchange Consideration under the Securities Act or any state securities
laws or to comply with the terms and conditions of any exemption thereunder (in each case). Notwithstanding the foregoing or anything
else contained herein to the contrary, the Exchange Consideration may be pledged as collateral in connection with a bona fide
margin account or other lending arrangement.

 

    	- 5 -

    	 	 	 

    

 

Share
Exchange Agreement

Quint
Media, Inc,/OncBioMune, Inc.

 

(g)
Legends. Each of the ONC Shareholders understand that the shares of the Company’s common stock that comprise the
Exchange Consideration (the “Securities”) and, until such time as the Securities has been registered under the Securities
Act may be sold pursuant to Rule 144 or Regulation S without any restriction as to the number of securities as of a particular
date that can then be immediately sold, the Securities may bear a restrictive legend in substantially the following form (and
a stop-transfer order may be placed against transfer of the certificates for such Securities):

 

NEITHER
THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I)
IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR
(B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE COMPANY), IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION
IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. 

 

The
legend set forth above shall be removed and the Company shall issue a certificate without such legend to the holder of any Securities
upon which it is stamped, if, unless otherwise required by applicable state securities laws, (a) the Securities are registered
for sale under an effective registration statement filed under the Securities Act or otherwise may be sold pursuant to Rule 144
or Regulation S without any restriction as to the number of securities as of a particular date that can then be immediately sold,
or (b) such holder provides the Company with an opinion of counsel, in form, substance and scope customary for opinions of counsel
in comparable transactions, to the effect that a public sale or transfer of such Exchange Shares may be made without registration
under the Securities Act, which opinion shall be accepted by the Company so that the sale or transfer is effected. Each of the
ONC Shareholders agrees to sell all Securities, including those represented by a certificate(s) from which the legend has been
removed, in compliance with applicable prospectus delivery requirements, if any.

 

(h)
Residency. Each of the ONC Shareholders is a resident of the jurisdiction set forth immediately below the ONC Shareholders’
name on the signature pages hereto or provided separately to the Company.

 

ARTICLE
II

REPRESENTATIONS,
COVENANTS, AND WARRANTIES OF THE COMPANY 

 

As
an inducement to, and to obtain the reliance of ONC and the ONC Shareholders, except as set forth in the Company Schedules (as
hereinafter defined), the Company represents and warrants, as of the date hereof and as of the Closing Date, as follows:

 

Section
2.01 Organization. The Company is a corporation duly organized, validly existing, and in good standing under the laws of
the State of Nevada and has the corporate power and is duly authorized under all applicable laws, regulations, ordinances, and
orders of public authorities to carry on its business in all material respects as it is now being conducted. Included in the Company
Schedules are complete and correct copies of the articles of incorporation and bylaws of the Company as in effect on the date
hereof. The execution and delivery of this Agreement does not, and the consummation of the transactions contemplated hereby will
not, violate any provision of the Company’s articles of incorporation or bylaws. The Company has taken all action required
by law, its articles of incorporation, its bylaws, or otherwise to authorize the execution and delivery of this Agreement, and
the Company has full power, authority, and legal right and has taken all action required by law, its articles of incorporation,
bylaws, or otherwise to consummate the transactions herein contemplated.

 

    	- 6 -

    	 	 	 

    

 

Share
Exchange Agreement

Quint
Media, Inc,/OncBioMune, Inc.

 

Section
2.02 Capitalization. At Closing, the Company’s authorized capitalization will consist of (a) 500,000,000 shares of
common stock, par value $0.0001 per share (“the Company Common Stock”), of which 3,000,000 shares will be issued and
outstanding, and (b) 20,000,000 shares of preferred stock, par value $.001 per share, of which zero (0) shares will be issued
and outstanding. Also at closing, the Company shall have designated 1,000,000 shares of Series A Preferred Stock whereby each
share of Series A Preferred Stock shall be entitled to 500 votes and will vote as a single class with the Common Stock on all
matters that come before shareholders for vote. All issued and outstanding shares are legally issued, fully paid, and non-assessable
and not issued in violation of the preemptive or other rights of any person and give effect to the Reverse Stock Split.

 

Section
2.03 Subsidiaries and Predecessor Corporations. Other than Exley Media, Inc., a Nevada corporation, the Company does not
have any predecessor corporation(s), no subsidiaries, and does not own, beneficially or of record, any shares of any other corporation.

 

Section
2.04 SEC Reports and Compliance.

 

(a)
The Company has filed all reports required to be filed by it by the Securities Exchange Act of 1934, as amended.

 

(b)
The Company is not an investment company within the meaning of Section 3 of the Investment Company Act of 1940, as amended.

 

(c)
The shares of Company Common Stock are quoted on the OTC Markets Group (the “OTC Markets”) under the symbol “QUNI”
and Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance in all material
respects with all rules and regulations of the OTC Markets applicable to it and the Company Common Stock. The issuance of Company
Common Stock under this Agreement does not contravene the rules and regulations of the trading market on which the Company Common
Stock is currently listed or quoted, and no approval of the stockholders of Company is required for Company to issue and deliver
the Company Common Stock contemplated by this Agreement.

 

(d)
Between the date hereof and the Effective Time, Company shall continue to satisfy the filing requirements of the Exchange Act
and all other requirements of applicable securities laws and of the OTC Markets.

 

(e)
The Company SEC Documents include all certifications and statements required of it, if any, by (i) Rule 13a-14 or 15d-14 under
the Exchange Act, and (ii) 18 U.S.C. Section 1350 (Section 906 of the Sarbanes-Oxley Act of 2002), and each of such certifications
and statements contain no qualifications or exceptions to the matters certified therein other than a knowledge qualification,
permitted under such provision, and have not been modified or withdrawn and neither Parent nor any of its officers has received
any notice from the Commission questioning or challenging the accuracy, completeness, form or manner of filing or submission of
such certifications or statements.

 

Section
2.05 Information. The information concerning the Company set forth in this Agreement and the Company Schedules is complete
and accurate in all material respects and does not contain any untrue statements of a material fact or omit to state a material
fact required to make the statements made, in light of the circumstances under which they were made, not misleading. In addition,
the Company has fully disclosed in writing to the ONC Shareholders (through this Agreement or the Company Schedules) all information
relating to matters involving the Company or its assets or its present or past operations or activities which (i) indicated or
may indicate, in the aggregate, the existence of a greater than $10,000 liability, (ii) have led or may lead to a competitive
disadvantage on the part of the Company or (iii) either alone or in aggregation with other information covered by this Section,
otherwise have led or may lead to a material adverse effect on the Company, its assets, or its operations or activities as presently
conducted or as contemplated to be conducted after the Closing Date, including, but not limited to, information relating to governmental,
employee, environmental, litigation and securities matters and transactions with affiliates.

 

    	- 7 -

    	 	 	 

    

 

Share
Exchange Agreement

Quint
Media, Inc,/OncBioMune, Inc.

 

Section
2.06 Options or Warrants. Except as disclosed on Company Schedule 2.06, there are no options, warrants, convertible securities,
subscriptions, stock appreciation rights, phantom stock plans or stock equivalents or other rights, agreements, arrangements or
commitments (contingent or otherwise) of any character issued or authorized by the Company relating to the issued or unissued
capital stock of the Company (including, without limitation, rights the value of which is determined with reference to the capital
stock or other securities of the Company) or obligating the Company to issue or sell any shares of capital stock of, or options,
warrants, convertible securities, subscriptions or other equity interests in, the Company. There are no outstanding contractual
obligations of the Company to repurchase, redeem or otherwise acquire any shares of the Company Common Stock of the Company or
to pay any dividend or make any other distribution in respect thereof or to provide funds to, or make any investment (in the form
of a loan, capital contribution or otherwise) in, any person.

 

Section
2.07 Absence of Certain Changes or Events. Since February 28, 2015 and except as disclosed in SEC Reports:

 

(a)
there has not been (i) any material adverse change in the business, operations, properties, assets or condition of the Company
or (ii) any damage, destruction or loss to the Company (whether or not covered by insurance) materially and adversely affecting
the business, operations, properties, assets or condition of the Company;

 

(b)
the Company has not (i) amended its articles of incorporation or bylaws except as required by this Agreement; (ii) declared or
made, or agreed to declare or make any payment of dividends or distributions of any assets of any kind whatsoever to stockholders
or purchased or redeemed, or agreed to purchase or redeem, any of its capital stock; (iii) waived any rights of value which in
the aggregate are outside of the ordinary course of business or material considering the business of the Company; (iv) made any
material change in its method of management, operation, or accounting; (v) entered into any transactions or agreements other than
in the ordinary course of business; (vi) made any accrual or arrangement for or payment of bonuses or special compensation of
any kind or any severance or termination pay to any present or former officer or employee; (vii) increased the rate of compensation
payable or to become payable by it to any of its officers or directors or any of its salaried employees whose monthly compensation
exceed $1,000; or (viii) made any increase in any profit sharing, bonus, deferred compensation, insurance, pension, retirement,
or other employee benefit plan, payment, or arrangement, made to, for or with its officers, directors, or employees;

 

(c)
The Company has not (i) granted or agreed to grant any options, warrants, or other rights for its stock, bonds, or other corporate
securities calling for the issuance thereof; (ii) borrowed or agreed to borrow any funds or incurred, or become subject to, any
material obligation or liability (absolute or contingent) except liabilities incurred in the ordinary course of business; (iii)
paid or agreed to pay any material obligations or liabilities (absolute or contingent) other than current liabilities reflected
in or shown on the most recent the Company balance sheet and current liabilities incurred since that date in the ordinary course
of business and professional and other fees and expenses in connection with the preparation of this Agreement and the consummation
of the transaction contemplated hereby; (iv) sold or transferred, or agreed to sell or transfer, any of its assets, properties,
or rights (except assets, properties, or rights not used or useful in its business which, in the aggregate have a value of less
than $1,000), or canceled, or agreed to cancel, any debts or claims (except debts or claims which in the aggregate are of a value
less than $1,000); (v) made or permitted any amendment or termination of any contract, agreement, or license to which it is a
party if such amendment or termination is material, considering the business of the Company; or (vi) issued, delivered or agreed
to issue or deliver, any stock, bonds or other corporate securities including debentures (whether authorized and unissued or held
as treasury stock), except in connection with this Agreement; and

 

    	- 8 -

    	 	 	 

    

 

Share
Exchange Agreement

Quint
Media, Inc,/OncBioMune, Inc.

 

(d)
to its knowledge, the Company has not become subject to any law or regulation which materially and adversely affects, or in the
future, may adversely affect, the business, operations, properties, assets or condition of the Company.

 

Section
2.08 Litigation and Proceedings There are no actions, suits, proceedings or investigations pending or, to the knowledge
of the Company after reasonable investigation, threatened by or against the Company or affecting the Company or its properties,
at law or in equity, before any court or other governmental agency or instrumentality, domestic or foreign, or before any arbitrator
of any kind except as disclosed in the Company Schedules. The Company has no knowledge of any default on its part with respect
to any judgment, order, writ, injunction, decree, award, rule or regulation of any court, arbitrator, or governmental agency or
instrumentality or any circumstance which after reasonable investigation would result in the discovery of such default.

 

Section
2.09 Contracts. 

 

(a)
The Company is not a party to, and its assets, products, technology and properties are not bound by, any leases, contract, franchise,
license agreement, agreement, debt instrument, obligation, arrangement, understanding or other commitments whether such agreement
is in writing or oral (“Contracts”).

 

(b)
The Company is not a party to or bound by, and the properties of the Company are not subject to any Contract, agreement, other
commitment or instrument; any charter or other corporate restriction; or any judgment, order, writ, injunction, decree, or award;
and

 

(c)
The Company is not a party to any oral or written (i) contract for the employment of any officer or employee; (ii) profit sharing,
bonus, deferred compensation, stock option, severance pay, pension benefit or retirement plan, (iii) agreement, contract, or indenture
relating to the borrowing of money, (iv) guaranty of any obligation, (vi) collective bargaining agreement; or (vii) agreement
with any present or former officer or director of the Company.

 

Section
2.10 No Conflict With Other Instruments The execution of this Agreement and the consummation of the transactions
contemplated by this Agreement will not result in the breach of any term or provision of, constitute a default under, or terminate,
accelerate or modify the terms of, any indenture, mortgage, deed of trust, or other material agreement or instrument to which
the Company is a party or to which any of its assets, properties or operations are subject.

 

Section
2.11 Compliance With Laws and Regulations The Company has complied with all United States federal, state or local or any
applicable foreign statute, law, rule, regulation, ordinance, code, order, judgment, decree or any other applicable requirement
or rule of law (a “Law”) applicable to the Company and the operation of its business. This compliance includes, but
is not limited to, the filing of all reports to date with federal and state securities authorities.

 

Section
2.12 Approval of Agreement The Board of Directors of the Company has authorized the execution and delivery of this
Agreement by the Company and has approved this Agreement and the transactions contemplated hereby.

 

Section
2.13 Material Transactions or Affiliations Except as disclosed herein and in the Company Schedules, there exists no contract,
agreement or arrangement between the Company and any predecessor and any person who was at the time of such contract, agreement
or arrangement an officer, director, or person owning of record or known by the Company to own beneficially, 5% or more of the
issued and outstanding common stock of the Company and which is to be performed in whole or in part after the date hereof or was
entered into not more than three years prior to the date hereof. Neither any officer, director, nor 5% Shareholders of the Company
has, or has had since inception of the Company, any known interest, direct or indirect, in any such transaction with the Company
which was material to the business of the Company. The Company has no commitment, whether written or oral, to lend any funds to,
borrow any money from, or enter into any other transaction with, any such affiliated person.

 

    	- 9 -

    	 	 	 

    

 

Share
Exchange Agreement

Quint
Media, Inc,/OncBioMune, Inc.

 

Section
2.14 The Company Schedules The Company has delivered to the ONC Shareholders the following schedules, which are
collectively referred to as the “Company Schedules” and which consist of separate schedules, which are dated the date
of this Agreement, all certified by the chief executive officer of the Company to be complete, true, and accurate in all material
respects as of the date of this Agreement.

 

(a)
a schedule containing complete and accurate copies of the articles of incorporation and bylaws of the Company as in effect as
of the date of this Agreement;

 

(b)
a schedule setting forth any information, together with any required copies of documents, required to be disclosed in the Company
Schedules by Sections 2.01 through 2.13.

 

The
Company shall cause the Company Schedules and the instruments and data delivered to the ONC Shareholders hereunder to be promptly
updated after the date hereof up to and including the Closing Date.

 

Section
2.15 Valid Obligation. This Agreement and all agreements and other documents executed by the Company in connection
herewith constitute the valid and binding obligation of the Company, enforceable in accordance with its or their terms, except
as may be limited by bankruptcy, insolvency, moratorium or other similar laws affecting the enforcement of creditors’ rights
generally and subject to the qualification that the availability of equitable remedies is subject to the discretion of the court
before which any proceeding therefore may be brought.

 

Section
2.16 Financial Statements. The balance sheets and statements of operations, stockholders’ equity and cash flows contained
in the Company SEC Documents (a) comply as to form in all material respects with applicable accounting requirements and rules
and regulations of the Commission with respect thereto, (b) have been prepared in accordance with U. S. GAAP applied on a basis
consistent with prior periods (and, in the case of unaudited financial information, on a basis consistent with year-end audits),
(c) are in accordance with the books and records of the Company and (d) present fairly in all material respects the financial
condition of the Company at the dates therein specified and the results of its operations and changes in financial position for
the periods therein specified.

 

Section
2.17 Shell Company. The Company is not now nor has it ever been a “shell company” as that term is defined in
Reg. 405 of the Securities Act of 1933, as amended.

 

Section
2.18 DTC Eligible. The Company’s Common Stock is DTC eligible and is not subject to any outstanding DTC “chills”
or “freezes”.

 

ARTICLE
III

SHARE EXCHANGE 

 

Section
3.01 The Exchange and Reverse Stock Split . Prior to the Share Exchange, the Company will reverse split its shares of common
stock on the basis of 1 share of common stock for each 138.73502066667 or such other number that shall result in reducing the
number of issued and outstanding shares of common stock, prior to Closing, to 3,000,000 shares. Fractional shares will be rounded
up to the next whole share. Fractional shares will not be issued. On the terms and subject to the conditions set forth in this
Agreement, on the Closing Date (as defined in Section 3.02), (i) the ONC Shareholders listed in Composite Exhibit A, representing
an aggregate of Forty-Seven Million (47,000,000) shares of ONC $0.0001 par value, common stock, upon their agreement, shall sell,
assign, transfer and deliver to the Company, free and clear of all liens, pledges, encumbrances, charges, restrictions or known
claims of any kind, nature, or description, all of the shares of ONC held by them as set forth on Composite Exhibit A; the objective
of such purchase (the “Exchange”) being the acquisition by the Company of not less than 100% of the issued and outstanding
shares of ONC $0.0001 par value, common stock. In exchange for the transfer of such securities by the ONC Shareholders as set
forth on Composite Exhibit A, the Company shall deliver to each such ONC Shareholders: one share of the Company’s $0.0001
par value, common stock and .0212765957446809 of the Company’s Series A Preferred Stock (the “Exchange Ratio”)
(the “Exchange Shares”) for each share of ONC $0.0001 par value, common stock (an aggregate of up to 47,000,000 shares
of the Company’s common stock). After the Share Exchange has been completed, the ONC shareholders will own 47,000,000 restricted
shares of common stock of the Company or 94% of the total outstanding shares of common stock of the Company and 1,000,000 shares
of Series A Preferred Stock or 100% of the total outstanding shares of preferred stock. Upon completion of the reverse stock split
and the issuance of the 47,000,000 shares of common stock to the ONC shareholders, there will be a total of 50,000,000 shares
of the Company’s common stock and 1,000,0000 shares of the Company’s Series A Preferred Stock outstanding. No other
securities of the Company will be outstanding other than the 50,000,000 shares of the Company’s common stock and 1,000,000
shares of the Company’s preferred stock. The Exchange Shares are hereinafter referred to as the “Exchange Consideration”
or the “Securities” and all such share amounts give effect to the Reverse Stock Split. At the Closing, the ONC Shareholders
shall, on surrender of their certificates representing their ONC shares to the Company or its registrar or transfer agent, be
entitled to receive a certificate or certificates evidencing their ownership of the Exchange Shares.

 

    	- 10 -

    	 	 	 

    

 

Share
Exchange Agreement

Quint
Media, Inc,/OncBioMune, Inc.

 

Section
3.02 Related Share Issuances. Other individuals and entities related to this transaction and/or ONC that receive shares
either at Closing or thereafter, shall receive such shares directly from the ONC Shareholders and not via new issuance from the
Company. Such individuals, include but are not limited to Barrett Ehrlich, Elliott Ehrlich, Andrew Kurcharchuk and Neal Holcomb.
For the avoidance of doubt it is the intent of the parties that the issuance of shares to these persons or their designees or
assigns, will not result in the ONC Shareholders owning in excess of 94% of the total issued and outstanding shares of Company
common stock on a fully diluted basis exclusive of the contemplated 1,000,000 shares of Series A Preferred Stock..

 

Section
3.03 Closing. The closing (“Closing”) of the transactions contemplated by this Agreement shall occur following
completion of the conditions set forth in Articles V and VI, and upon delivery of the Exchange Consideration as described in Section
3.01 herein. The Initial Closing shall take place at a mutually agreeable time and place and is anticipated to close by no later
than August 31, 2015, but in no event before this Agreement has been signed by ONC Shareholders holding at least 100% of the shares
of ONC $0.001 par value, common stock outstanding (the “Closing Date”).

 

Section
3.04 Closing Events. At the Closing, the Company, and ONC shall execute, acknowledge, and deliver (or shall ensure
to be executed, acknowledged, and delivered), any and all certificates, opinions, financial statements, schedules, agreements,
resolutions, rulings or other instruments required by this Agreement to be so delivered at or prior to the Closing, together with
such other items as may be reasonably requested by the parties hereto and their respective legal counsel in order to effectuate
or evidence the transactions contemplated hereby.

 

Section
3.05 Termination. This Agreement may be terminated by each of the ONC Shareholders or the Company only (a) in the event
that the Company or ONC do not meet the conditions precedent set forth in Articles V and VI or (b) if the Initial Closing has
not occurred by August 31, 2015. If this Agreement is terminated pursuant to this section, this Agreement shall be of no further
force or effect as to any party hereto, and no obligation, right or liability shall arise hereunder.

 

ARTICLE
IV

SPECIAL COVENANTS

 

Section
4.01 Access to Properties and Records. The Company and ONC will each afford to the officers and authorized representatives
of the other full access to the properties, books and records of the Company or ONC, as the case may be, in order that each may
have a full opportunity to make such reasonable investigation as it shall desire to make of the affairs of the other, and each
will furnish the other with such additional financial and operating data and other information as to the business and properties
of the Company or ONC, as the case may be, as the other shall from time to time reasonably request. Without limiting the foregoing,
as soon as practicable after the end of each fiscal quarter (and in any event through the last fiscal quarter prior to the Closing
Date), each party shall provide the other with quarterly internally prepared and unaudited financial statements.

 

Section
4.02 Delivery of Books and Records. At the Closing, ONC shall deliver to the Company, the originals of the corporate
minute books, books of account, contracts, records, and all other books or documents of ONC now in the possession of ONC or its
representatives.

 

    	- 11 -

    	 	 	 

    

 

Share
Exchange Agreement

Quint
Media, Inc,/OncBioMune, Inc.

 

Section
4.03 Third Party Consents and Certificates. The Company and ONC agree to cooperate with each other in order to obtain
any required third party consents to this Agreement and the transactions herein contemplated.

 

Section
4.04 Actions Prior to Closing. From and after the date hereof until the Closing Date and except as set forth in
the Company Schedules or ONC Schedules or as permitted or contemplated by this Agreement, the Company (subject to paragraph (d)
below) and ONC respectively, will each:

 

(a)
carry on its business in substantially the same manner as it has heretofore and as disclosed in the Company OTC Reports;

 

(b)
maintain and keep its properties in states of good repair and condition as at present, except for depreciation due to ordinary
wear and tear and damage due to casualty;

 

(c)
maintain in full force and effect insurance comparable in amount and in scope of coverage to that now maintained by it;

 

(d)
perform in all material respects all of its obligations under material contracts, leases, and instruments relating to or affecting
its assets, properties, and business;

 

(e)
use its best efforts to maintain and preserve its business organization intact, to retain its key employees, and to maintain its
relationship with its material suppliers and customers; and

 

(f)
fully comply with and perform in all material respects all obligations and duties imposed on it by all federal and state laws
(including without limitation, the federal securities laws) and all rules, regulations, and orders imposed by federal or state
governmental authorities.

 

(g)
From and after the date hereof until the Closing Date, except as required by this Agreement neither the Company nor ONC will:

 

(i)
make any changes in their Articles of Incorporation, articles or articles of incorporation or bylaws except as contemplated by
this Agreement including a name change;

 

(ii)
take any action described in Section 1.07 in the case of ONC or in Section 2.07, in the case of the Company (all except as permitted
therein or as disclosed in the applicable party’s schedules);

 

(iii)
enter into or amend any contract, agreement, or other instrument of any of the types described in such party’s schedules,
except that a party may enter into or amend any contract, agreement, or other instrument in the ordinary course of business involving
the sale of goods or services; or

 

(iv)
sell any assets or discontinue any operations, sell any shares of capital stock or conduct any similar transactions other than
in the ordinary course of business except as disclosed in the Company OTC Reports.

 

ARTICLE
V

CONDITIONS PRECEDENT TO OBLIGATIONS OF THE COMPANY

 

The
obligations of the Company under this Agreement are subject to the satisfaction, at or before the Closing Date, of the following
conditions:

 

Section
5.01 Accuracy of Representations and Performance of Covenants. The representations and warranties made by ONC and
the ONC Shareholders in this Agreement were true when made and shall be true at the Closing Date with the same force and effect
as if such representations and warranties were made at and as of the Closing Date (except for changes therein permitted by this
Agreement). ONC shall have performed or complied with all covenants and conditions required by this Agreement to be performed
or complied with by ONC prior to or at the Closing. The Company shall be furnished with a certificate, signed by a duly authorized
executive officer of ONC and dated the Closing Date, to the foregoing effect.

 

    	- 12 -

    	 	 	 

    

 

Share
Exchange Agreement

Quint
Media, Inc,/OncBioMune, Inc.

 

Section
5.02 Officer’s Certificate. The Company shall have been furnished with a certificate dated the Closing
Date and signed by a duly authorized officer of ONC to the effect that no litigation, proceeding, investigation, or inquiry is
pending, or to the best knowledge of ONC threatened, which might result in an action to enjoin or prevent the consummation of
the transactions contemplated by this Agreement, or, to the extent not disclosed in the ONC Schedules, by or against ONC, which
might result in any material adverse change in any of the assets, properties, business, or operations of ONC.

 

Section
5.03 Good Standing. The Company shall have received a certificate of good standing from the Secretary of
State of Nevada or other appropriate office, dated as of a date within ten days prior to the Closing Date certifying that ONC
is in good standing as a corporation in the State of Nevada.

 

Section
5.04 Minimum ONC Shareholders. This Agreement shall have been signed by the holders of not less than 100%
of the ONC common stock, including voting power, of ONC, unless a lesser number is agreed to by the Company.

 

Section
5.05 No Governmental Prohibition. No order, statute, rule, regulation, executive order, injunction, stay, decree,
judgment or restraining order shall have been enacted, entered, promulgated or enforced by any court or governmental or regulatory
authority or instrumentality which prohibits the consummation of the transactions contemplated hereby.

 

Section
5.06 Consents. All consents, approvals, waivers or amendments pursuant to all contracts, licenses, permits, trademarks
and other intangibles in connection with the transactions contemplated herein, or for the continued operation of ONC after the
Closing Date on the basis as presently operated shall have been obtained.

 

Section
5.07 Other Items.

 

(a)
The Company shall have received a list containing the name, address, and number of shares held by the ONC Shareholders as of the
date of Closing, certified by an executive officer of ONC as being true, complete and accurate; and

 

(b)
The Company shall have received such further opinions, documents, certificates or instruments relating to the transactions contemplated
hereby as the Company may reasonably request.

 

(c)
The Company shall have received the ONC Financial Statements as provided for in Sections 1.04(a) and (b).

 

ARTICLE
VI

CONDITIONS PRECEDENT TO OBLIGATIONS OF ONC

AND THE ONC SHAREHOLDERS

 

The
obligations of ONC and each of the ONC Shareholders under this Agreement are subject to the satisfaction of the Company, or each
ONC Shareholder, as the case may be, at or before the Closing Date, of the following conditions:

 

Section
6.01 Accuracy of Representations and Performance of Covenants. The representations and warranties made by the Company
in this Agreement were true when made and shall be true as of the Closing Date (except for changes therein permitted by this Agreement)
with the same force and effect as if such representations and warranties were made at and as of the Closing Date. Additionally,
the Company shall have performed and complied with all covenants and conditions required by this Agreement to be performed or
complied with by the Company.

 

    	- 13 -

    	 	 	 

    

 

Share
Exchange Agreement

Quint
Media, Inc,/OncBioMune, Inc.

 

Section
6.02 Officer’s Certificate. ONC shall have been furnished with certificates dated the Closing Date
and signed by duly authorized executive officers of the Company, to the effect that no litigation, proceeding, investigation or
inquiry is pending, or to the best knowledge of the Company threatened, which might result in an action to enjoin or prevent the
consummation of the transactions contemplated by this Agreement or, to the extent not disclosed in the Company Schedules, by or
against the Company, which might result in any material adverse change in any of the assets, properties or operations of the Company.

 

Section
6.03 Good Standing. ONC shall have received a certificate of good standing from the Secretary of State of
Louisiana or other appropriate office, dated as of a date within ten days prior to the Closing Date certifying that the Company
is in good standing as a corporation in the State of Louisiana and has filed all tax returns required to have been filed by it
to date and has paid all taxes reported as due thereon.

 

Section
6.04 No Governmental Prohibition. No order, statute, rule, regulation, executive order, injunction, stay, decree,
judgment or restraining order shall have been enacted, entered, promulgated or enforced by any court or governmental or regulatory
authority or instrumentality which prohibits the consummation of the transactions contemplated hereby.

 

Section
6.05 Approval by the Company Board of Directors and its Shareholders. The Company’s board of directors shall have
approved the Exchange and completed the following (the “Corporate Actions”):

 

(a)
effect a reverse split such that the total outstanding shares of the Company’s issued and outstanding common stock at Closing
is 3,000,000. The reverse split ratio shall be approximately 1:138.73502066667 (the “Reverse Stock Split”);

 

(b)
change the name of the Company to OncBioMune Pharmaceauticals, Inc.

 

(c)
designate 1,000,000 shares of Series A Preferred Stock with each share of Series A Preferred Stock being entitled to 500 votes
on all matters submitted to the shareholders of the Company for vote.

 

Section
6.06 Consents. All consents, approvals, waivers or amendments pursuant to all contracts, licenses, permits, trademarks
and other intangibles in connection with the transactions contemplated herein, or for the continued operation of the Company after
the Closing Date on the basis as presently operated shall have been obtained including approval of the Corporate Actions by FINRA.

 

Section
6.07 Shareholder Report The ONC Shareholders shall receive a shareholder’s report reflective of all the Company
shareholder’s which does not exceed 3,000,000 shares of the Company $0.0001 par value, common stock (after giving effect
to the Reverse Stock Split) issued and outstanding as of the day prior to the Closing Date and no shares of preferred stock outstanding.

 

Section
6.08 Other Items.

 

(a)
The ONC Shareholders shall have received further opinions, documents, certificates, or instruments relating to the transactions
contemplated hereby as the ONC Shareholders may reasonably request.

 

(b)
This Agreement shall have been executed by the holders of at least 100% of the shares of ONC common stock.

 

    	- 14 -

    	 	 	 

    

 

Share
Exchange Agreement

Quint
Media, Inc,/OncBioMune, Inc.

 

(c)
Appointment of Directors and Officers. The Company shall have appointed Robert L. Elliott, M.D., Jonathan F. Head, Ph. D. and
Andrew Kucharchuk as directors of the Company;

 

(d)
Contantin Dietrich and any other directors and officers, as applicable, shall have resigned as Director and from all officer positions
with the Company;

 

ARTICLE
VII

MISCELLANEOUS

 

Section
7.01 Brokers. The Company and ONC agree that there were no finders or brokers involved in bringing the parties
together or who were instrumental in the negotiation, execution or consummation of this Agreement, with the exception of Barrett
Ehrlich. Mr. Ehrlich acted only as a “finder” as that term is defined in the decisions of the Securities and Exchange
Commission. The Company and ONC each agree to indemnify the other against any claim by any third person other than those described
above for any commission, brokerage, or finder’s fee arising from the transactions contemplated hereby based on any alleged
agreement or understanding between the indemnifying party and such third person, whether express or implied from the actions of
the indemnifying party.

 

Section
7.02 Governing Law. This Agreement shall be governed by, enforced, and construed under and in accordance
with the laws of the State of Nevada, without giving effect to the principles of conflicts of law thereunder. Each of the parties
(a) irrevocably consents and agrees that any legal or equitable action or proceedings arising under or in connection with this
Agreement shall be brought exclusively in the state or federal courts of the United States with jurisdiction in Palm Beach County,
Florida. By execution and delivery of this Agreement, each party hereto irrevocably submits to and accepts, with respect to any
such action or proceeding, generally and unconditionally, the jurisdiction of the aforesaid courts, and irrevocably waives any
and all rights such party may now or hereafter have to object to such jurisdiction.

 

Section
7.03 Notices. Any notice or other communications required or permitted hereunder shall be in writing and
shall be sufficiently given if personally delivered to it or sent by telecopy, overnight courier or registered mail or certified
mail, postage prepaid, addressed as follows:

 

	If
    to ONC, to: 	 	If
    to the Company, to: 
	 	 	 
	Oncbiomune,
    Inc.	 	Constantin
    Dietrich, Chief Executive Officer
	Attn:
    Andrew Kucharchuk	 	Quint
    Media, Inc.
	17050
    Medical Center Drive, 4th Floor	 	330
    Clematis Street, Suite 217
	Baton
    Rouge, LA 70816-3251	 	West
    Palm Beach, FL 33401

 

or
such other addresses as shall be furnished in writing by any party in the manner for giving notices hereunder, and any such notice
or communication shall be deemed to have been given (i) upon receipt, if personally delivered, (ii) on the day after dispatch,
if sent by overnight courier, (iii) upon dispatch, if transmitted by telecopy and receipt is confirmed by telephone and (iv) three
(3) days after mailing, if sent by registered or certified mail.

 

Section
7.04 Attorney’s Fees. In the event that either party institutes any action or suit to enforce this
Agreement or to secure relief from any default hereunder or breach hereof, the prevailing party shall be reimbursed by the losing
party for all costs, including reasonable attorney’s fees, incurred in connection therewith and in enforcing or collecting
any judgment rendered therein.

 

Section
7.05 Confidentiality. Each party hereto agrees with the other that, unless and until the transactions contemplated
by this Agreement have been consummated, it and its representatives will hold in strict confidence all data and information obtained
with respect to another party or any subsidiary thereof from any representative, officer, director or employee, or from any books
or records or from personal inspection, of such other party, and shall not use such data or information or disclose the same to
others, except (i) to the extent such data or information is published, is a matter of public knowledge, or is required by law
to be published; or (ii) to the extent that such data or information must be used or disclosed in order to consummate the transactions
contemplated by this Agreement. In the event of the termination of this Agreement, each party shall return to the other party
all documents and other materials obtained by it or on its behalf and shall destroy all copies, digests, work papers, abstracts
or other materials relating thereto, and each party will continue to comply with the confidentiality provisions set forth herein.

 

    	- 15 -

    	 	 	 

    

 

Share
Exchange Agreement

Quint
Media, Inc,/OncBioMune, Inc.

 

Section
7.06 Public Announcements and Filings. Unless required by applicable law, including the Securities Exchange
Act, or regulatory authority, none of the parties will issue any report, statement or press release to the general public, to
the trade, to the general trade or trade press, or to any third party (other than its advisors and representatives in connection
with the transactions contemplated hereby) or file any document, relating to this Agreement and the transactions contemplated
hereby, except as may be mutually agreed by the parties. Copies of any such filings, public announcements or disclosures, including
any announcements or disclosures mandated by law or regulatory authorities, shall be delivered to each party at least one (1)
business day prior to the release thereof.

 

Section
7.07 Schedules; Knowledge. Each party is presumed to have full knowledge of all information set forth in
the other party’s schedules delivered pursuant to this Agreement.

 

Section
7.08 Third Party Beneficiaries. This contract is strictly between the Company, the ONC Shareholders and ONC, and,
except as specifically provided, no director, officer, stockholder (other than the ONC Shareholders), employee, agent, independent
contractor or any other person or entity shall be deemed to be a third party beneficiary of this Agreement.

 

Section
7.09 Expenses. Subject to Section 7.04 above, whether or not the Exchange is consummated, each of the Company
and ONC will bear their own respective expenses, including legal, accounting and professional fees, incurred in connection with
the Exchange or any of the other transactions contemplated hereby.

 

Section
7.10 Entire Agreement. This Agreement represents the entire agreement between the parties relating to the
subject matter thereof and supersedes all prior agreements, understandings and negotiations, written or oral, with respect to
such subject matter.

 

Section
7.11 Survival; Termination. The representations, warranties, and covenants of the respective parties shall survive
the Closing Date and the consummation of the transactions herein contemplated for a period of two years.

 

Section
7.12 Counterparts. This Agreement may be executed in multiple counterparts, each of which shall be deemed an original
and all of which taken together shall be but a single instrument.

 

Section
7.13 Amendment or Waiver. Every right and remedy provided herein shall be cumulative with every other right
and remedy, whether conferred herein, at law, or in equity, and may be enforced concurrently herewith, and no waiver by any party
of the performance of any obligation by the other shall be construed as a waiver of the same or any other default then, theretofore,
or thereafter occurring or existing. At any time prior to the Closing Date, this Agreement may by amended by a writing signed
by all parties hereto, with respect to any of the terms contained herein, and any term or condition of this Agreement may be waived
or the time for performance may be extended by a writing signed by the party or parties for whose benefit the provision is intended.

 

Section
7.14 Best Efforts. Subject to the terms and conditions herein provided, each party of ONC and the Company shall
use its best efforts to perform or fulfill all conditions and obligations to be performed or fulfilled by it under this Agreement
so that the transactions contemplated hereby shall be consummated as soon as practicable. Each party of ONC and the Company also
agrees that it shall use its best efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things
necessary, proper or advisable under applicable laws and regulations to consummate and make effective this Agreement and the transactions
contemplated herein.

 

    	- 16 -

    	 	 	 

    

 

Share
Exchange Agreement

Quint
Media, Inc,/OncBioMune, Inc.

 

IN
WITNESS WHEREOF, the corporate parties hereto have caused this Agreement to be executed by their respective officers, hereunto
duly authorized, as of the date first-above written.

 

	 	QUINT
    MEDIA, INC.
	 	A
    Nevada corporation
	 	 	 
	 	By:	/s/
    Constantin Dietrich 
	 	 	Constantin Dietrich,
    CEO
	 	 	 
	 	ONCBIOMUNE,
    INC.
	 	A
    Louisiana corporation
	 	 	 
	 	By:	/s/
    Robert Elliot
	 	 	Robert L. Elliot,
    M.D., President

 

    	- 17 -

    	 	 	 

    

 

Share
Exchange Agreement

Quint
Media, Inc,/OncBioMune, Inc.

 

COMPOSITE
EXHIBIT A

 

ONCBIOMUNE,
INC. SHAREHOLDERS SIGNATURE PAGE

 

	 	Purchaser
    Name	 	No.
    Shares of ONC Common Stock	 	%
    of ONC’s Outstanding Shares	 	 	No.
    Shares of the Company’s Common Stock	 	%
    of 

    Company’s Outstanding Shares	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Robert
                                         L. Elliott, M.D.

	 	23,500,000
	 	50.00
	%	 	23,500,000
	 	47.0	%
	Sign:	/s/
    Robert Elliott	 	 	 	 	 	 	 	 	 	 
	Name:	Robert L. Elliott,
    M.D.	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Jonathan
    F. Head, Ph. D.	 	23,500,000	 	50.00	%	 	23,500,000	 	47.0	%
	 	 	 	 	 	 	 	 	 	 	 	 
	Sign:	/s/
    Jonathan Head	 	 	 	 	 	 	 	 	 	 
	Name:	Jonathan F. Head,
    Ph. D.	 	 	 	 	 	 	 	 	 	 

 

    	- 18 -

    	 	 	 

    

 

EXHIBIT
B

 

FORM
OF AMENDED AND RESTATED ARTICLES

 

    	- 1 -

    	 	 	 

    

 

QUINT
MEDIA, INC. – ONCBIOMUNE, INC.

 

Share
Exchange Agreement

 

SCHEDULES

 

    	- 2 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}]]